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ENGINEERING HYALURONIC ACID FOR BIOMEDICAL APPLICATIONS

Deep S Bhattacharya, Ph.D.
University of Nebraska, 2019
Supervisor: Aaron M. Mohs, Ph.D.
This work presents research using the naturally available non-sulfated
carbohydrate glycosaminoglycan hyaluronic acid (HA) for the synthesis of different
chemical derivatives of HA for evaluation of binding kinetics with CD44 and Pselectin proteins for applications in fluorescence image-guided surgery. Chemical
derivatives of HA such as deacetylated HA (deHA), sulfated HA (sHA), and
deacetylated and sulfated HA (s-deHA) were synthesized by modulating sulfating
and deacetylating reagents to alter binding specificities to CD44. Modified HA
derivatives and CD44 biophysical interactions were assessed by fluorescence
polarization. In silico techniques were also used to determine binding using
molecular docking and MM-PBSA approaches. Both modifications represent the
first step to effectively re-target HA-based materials. Re-targeting HA was
successfully conducted by tuning the sulfate distribution on HA to P-selectin.
Sulfate modifications render HA with dual-targeting potential to both CD44 and Pselectin. Three derivatives of HA were synthesized by controlling the sulfation
agent to give selectively sulfated HA (ssHA), moderately sulfated HA (msHA), and
completely sulfated HA (csHA). The strongest binding was observed for the csHA
with recombinant P-selectin when compared with fucoidan. Amphiphilic conjugates

viii
were prepared for the three derivatives of HA by conjugating a hydrophobic ligand
(1-pyrenebutanamide- PBA) followed by chemical conjugation of Cyanine7.5 dye
to give near-infrared fluorescent nanoparticles. Modified HA nanoparticles were
assessed for uptake in P-selectin and CD44 positive cells along with knockout cell
lines. Preference for P-selectin mediated uptake was observed in vitro binding
assays. In vivo performance for image-guided surgery applications indicated
higher uptake of sulfated HA nanoparticles compared to non-sulfated HA
nanoparticles in S2-013 tumors grown subcutaneously in nude mice. HA as a nontoxic, biocompatible material is an ideal precursor for generating newer imaging
probes for biomedical applications. HA as a non-fluorescent precursor was
conjugated with non-fluorescent biocompatible amino acids to form a novel
fluorescent organic nanoparticle (FONPs) using one-pot green chemistry
conditions. The FONPs exhibited high water solubility due to the existence of
hydrophilic functional groups on its surface, acceptable stability profiles, superior
biocompatibility, and high quantum yield photo-luminescent properties. Also, the
FONPs demonstrated drug carrier properties with enhanced drug loading and
delivery of the anticancer drug doxorubicin (DOX) in cancer cells and 3D tumor
spheroid model. Results demonstrate the efficacy of a novel fluorescent HA-based
with potential future applications in image-guided drug delivery.
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CHAPTER I
INTRODUCTION
1.1 CD44 Introduction
CD44, a cell surface glycoprotein also referred to as P-glycoprotein1 part of a
larger group of hyaluronan-binding proteins, termed hyaladherins2 is highly
expressed in many cancers which regulate metastasis. A single gene encodes
CD44 on a chromosome locus 11p133 with a molecular weight of 75-150 kDa4.
The standard CD44 is post-translated from the transcription of exons 1-5 and 16205 that are spliced together by protein-development machinery in the cell giving
rise to primary domains of CD44 as extracellular or ectodomain, transmembrane,
and cytoplasmic domains (Figure 1)6.
The primary binding domain of CD44 which is homologous to B loop of cartilage
binding link proteins7 coined a link module is responsible for binding/interacting
with external microenvironment and hyaluronic acid8. The transmembrane
domain of the protein is involved in interacting with co-factors, adaptor proteins,
and ions9. The intracellular domain has a short-and long-tail spliced configuration
which functions with multiple downstream and nuclear factors responsible for
localization and mediation of cellular responses such as growth-promoting tumor
receptor tyrosine kinases10,11,12. CD44 is also involved in other cellular functions
such as proliferation, cellular migration, differentiation, angiogenesis, protease
docking, cell survival, chemokines and growth factors, and adhesive
properties13,14,15,16.
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Dynamic regulation of actin cytoskeleton with different CD44 conformations is
involved in migration of and interactions of matrix metalloproteinase 9 (MMP9)
with various cancer cells17,18. Abundant literature reports highlight the
clinicopathological importance of cancer cells by undergoing epithelial to
mesenchymal transition acquiring stem-cell-like properties promote increased
CD44 expression for proliferation, adhesion, migration, and invasion19,20,21.

1.2 CD44 composition
CD44, a single non-kinase transmembrane glycoprotein was first cloned in
198922, gene derived from a single copy of located on the short arm of human
chromosome 11 and chromosome 2 in mice species, roughly extending 50 kb in
genomic DNA13. The protein varies in molecular size due to differences in
glycosylation patterns (O-and N-glycosylation) in the extracellular domains23,24.
CD44 proteins contain roughly ten variants varying between gene 5 and gene 16
with insertions of different lengths governing the splicing and transcription of final
protein25. The ligand-binding domain in the extracellular space and the protein
has a half-life of 8 h26. Theoretically, 900 CD44-isoforms can be generated by
alternative gene-splicing among exons, but all of them are not expressed by the
cell.
The standard form of CD44 is the most abundantly found variant of CD44,
which contains six potential phosphorylation sites in the intracellular variable
fragment. All the other variants are glycosylated mostly at the asparagine or
serine sites located dispersed in the extra-cellular domain27.
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Figure 1: (a) Four domains of CD44 glycoprotein are presented with
corresponding colors: ligand binding domain, variable domain, transmembrane
domain, and cytoplasmic tail. (b) CD44 is encoded by 20 exons in mice but 19
exons in humans. Exon 6 coding for CD44 variant 1 (CD44v1) is lacking in
humans. Green color exons are always expressed as a standard form of CD44
(CD44s), and up to nine exon variants can be inserted by alternative splicing.
Full-length CD44, CD44s, CD44v3, CD44v6, and CD44v8-10 are shown
schematically
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1.3. Functional significance of CD44 and molecular targets in cancer and
non-cancerous cells
The role of CD44 and its isoforms expression plays a vital in the pathogenesis
of cancer. Distribution of both is widely found in healthy adult and fetal states of
evolution28. The CD44 standard protein was initially isolated from tissues of the
central nervous system, lung, and epidermis, which were part of the
hematopoietic cellular system29. In healthy tissues, keratinocytes, macrophages,
epithelial cells, CD44 play a vital role in regulation of hyaluronic acid (HA)
metabolism and turnover, lymphocyte activation, the release of cytokines, wound
healing, and proliferation. CD44 in cancerous states play a significant role in
metastasis at distant sites for growth30. CD44 is also defined as cancer-initiating
cell marker due to its cross-talk with multiple cell types. Cell-to-cell or cell-tomatrix interactions involving CD44 might protect tumor cells recognition from the
immune system, facilitating colonization. Levels of CD44 and its variants can be
used in assessments of resected tumor biopsies for prognosis and neoplastic
properties of diseases.
CD44 along with its variants can undergo dynamic switching depending on
tumor phenotype, e.g., pancreatic cancer cells were mainly dependent on
upregulation of standard CD44 and variant 631; prostate cancer cells that are
benign express higher CD44 variant 5; breast cancer cells have abnormal
expression profiles of both CD44 and multiple isoforms28. Among the many CD44
functions, it plays a significant role in transforming cell lines that are nonmetastatic by altering the adaptive plasticity to more fiercely positive metastatic
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behavior32. CD44 and its variants are also related to the poor prognosis in
colorectal

cancer.

Clinicopathological

characteristics

and

prognosis

of

gastrointestinal patients are linked to higher expression of CD44 variant 6 and
variant 9 along with standard CD44 expression31. Varying molecular biology
techniques have evaluated CD44 expression in normal and cancerous cells, and
the association of a gradual increase in CD44 expression from less malignant to
more advanced stages is another indication of importance in the cancer
progression/malignant process33. CD44 and its isoforms are also highly
expressed in thyroid carcinoma, hepatocellular carcinoma, renal cell carcinoma,
endometrial cancer, and ovarian cancer carcinoma.
CD44 is known to interact with various signaling pathways such as protein
kinases playing a crucial role in drug resistance and tumor invasiveness
properties34; cytoskeletal alterations in Ezrin-Radixin-Moesin pathway by altering
phosphorylation patterns in other pathways35; modulation of transcriptional
factors and pathways such as hippo signaling36, β-catenin pathway37, TGF-β38,
Emmprin (CD147)39, and STAT340.
Hyaluronidases also termed as “spreading factor” that degrades high
molecular weight HA to lower molecular weight in the extracellular matrix41. The
enzyme also has clinical relevance as degradation of HA by hyaluronidases is
known to facilitate tumor invasiveness by the support of CD44-HA interactions,
mediating cell migration, and spreading42. Extensive degradation of HA in the
extracellular matrix might for pockets, reducing the viscosity of HA, giving room
for tumor cells to invade and spread. A previous study reported elevated levels
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of hyaluronidases with increasing degree of colon carcinoma43. However, many
factors, such as tumor type variance, hyaluronidase enzyme isotype, the
molecular weight of HA in the matrix, might influence the degradation kinetics and
role in cancer spreading.
1.4. CD44 structure, ligands, and biophysical mechanism of hyaluronic
acid binding
CD44, a type I transmembrane protein, interacts with HA as its primary ligand
via link module44. Structurally, the canonical form of human CD44 consists of 723
residues, divided into four distinct domains. The important extracellular HA
binding domain is conserved, which contains an α/β-fold consisting of
approximately 158-residues in length45. The link module, comprising of Nterminal and C-terminal flanking regions with six β-strands and two α-helices
similar to C-type lectin domain, form the globular HA-binding unit stabilized by
three disulfide bridges46. The binding regions also interact with similar HA-binding
proteins, such as TSG-647 and LYVE-148. Majority of the binding domain to HA is
also retained in the soluble portion of the protein allowing successful protein
expression and purification.
Currently, there is only one crystal structure of CD44 bound to HA been used
extensively for two decades46. The CD44 protein shows substantial selectivity for
recognition of HA over other carbohydrate glycosaminoglycans due to its highly
specific interactions. HA has shown to bind to the shallow binding groove of the
active site with multiple specific hydrogen bonds and van-der-wall interactions
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along with smaller pockets of hydrophobic patches to accommodate the methyl
group of N-acetyl glucosamine49. Other interactions include oxygen atoms of the
carboxylate group forming hydrogen bonds; the N-acetyl group forms
hydrophobic and multiple water-mediated hydrogen bonds. Lacking critical CH-p
interactions in the complex is characteristic of the protein-carbohydrate complex.
The minimum number of units that can bind to CD44 has been reported to be an
octamer-variant of HA. This specificity arises due to the characteristics peculiar
to glucuronic acid and N-acetyl glucosamine repeat units in HA50.
The crystallographic complex of HA-CD44 has been shown to exist in two
conformation states (called “A” and “B”). CD44 HABD exchanges its conformation
between ordered (O) and partially disordered (PD) states in either the absence
or presence of the HA ligand, respectively. This change in conformation causes
“B” conformation to correspond to more intimate contact between HA and CD44
compared to conformation “A”. This interconversion between two distinct
conformations has the exchange rate of hundreds of milliseconds51. Thirteen
critical residues in the Link binding-module (Arg45, Tyr46, Cys81, Arg82, Tyr83,
Ile92, Asn98, Ile100, Cys101, Ala102, Ala103, His105, and Tyr109) make
contacts with HA, and there is a notably large contribution from aliphatic side
chains to HA binding (including Ile92, Ile100, Ala102, and Ala103, which are all
located in the β4-β5 loop). The remainder of the binding groove is lined by
aromatic and basic residues (Arg45, Tyr46, Arg82, and Tyr83) brought together
from the β1-α1 and α2-β3 loops, together with Tyr109 from the β5 strand. HAbinding surface on CD44 on the link domain also found (R29, K38, R41) and
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another in the C-terminal extension (R150, R154, K158, R162)—to be crucial for
the binding. N-glycosylation post-translational modifications also have a crucial
role in HA binding, as negatively charged sialic acid can impede interactions of COOH of HA with basic residues in the active site52. Such interactions can be
exploited to modulate interactions of HA with CD44.

Figure 2: (a) Final 1.25 -Å-resolution electron density for the binding site of CD44
with hyaluronic acid polymer generated by SIGMAA. (b) A ribbon diagram of
mouse Cd44 (type B complex), with secondary structure identified using the
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DSSP algorithm33. Pink, α-helices; white, loops; green and gold, β-sheets I and
II, respectively; cyan, bound HA. (c) Surface representation of the HA-binding site
in the type B crystal complex. The shallow HA-binding groove is shown as
molecular surface. Gold, supplementary lobe formed from N- and C-terminal Link
extensions; cyan, HA. Selected residues marking the boundaries of the groove
are labeled. The type A crystal form shows similar features but lacks the lower
platform for the HA interaction provided by reorientation of Arg45.
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1.5. Hyaluronic acid structure, cell surface receptors, and its chemical
modifications thereof
HA is a linear polysaccharide composed of alternating units of D-glucuronic
acid and N-acetyl-D-glucosamine with β-(1→4) glycoside linkage between the
two units and with no known post-synthetic modifications. HA amongst all other
glycosaminoglycan is the only non-sulfated variant in the extracellular matrix and
synovial fluid, making it uniquely popular for applications in the field of
biomaterials53. The unique β-bond configuration renders the carbohydrate a very
energetically-stable structure, with its functional groups in favorable equatorial
positions. HA exists as negatively charged molecule in an aqueous solution in
which readily forms salts generally termed as hyaluronan or hyaluronate54. In
solution, HA forms a double-fold helical duplex with an interplay of hydrophobic
CH groups and inter-molecular H-bonds, enabling the formation of the mesh
network. HA solutions display a non-Newtonian, shear-thinning, and viscoelastic
behavior55 (Figure 3).
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Figure 3:

Chemical structures of HA disaccharide unit (A) and HA

tetrasaccharide unit where the hydrophilic functional groups and the hydrophobic
moieties are respectively evidenced in blue and yellow, while the hydrogen bonds
are represented by green dashed lines (B).
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HA is uniquely synthesized by hyaluronan synthase (HAS1, 2, 3) at the inner
face of the plasma membrane rather than in the Golgi apparatus without any
covalent bond to a protein core, unlike any typical glycosaminoglycans such as
heparin sulfate, chondroitin sulfate, dermatan sulfate, keratin sulfate etc56. The
average content of HA in a 70-kg adult is about 15 g forming the pericellular
coating and extracellular matrix (ECM) in connective tissues57. Hyaluronan
degrades to glucuronic acid and N-acetylglucosamine in lysosomes (pH 3-4) and
is metabolized by hepatocytes to CO2, H2O and urea.
The balance between the synthesis and degradation of HA plays an essential
regulatory function in determining the molecular weight of HA generated. HA,
according to the vast array of literature reports, performs two underlying biological
mechanisms: passive structural molecule and as a signaling moiety, both
dependent on the size of HA generated in the body58. High molecular weight HA
plays an important role in inflammation, tissue injury and repair, wound healing,
and immunosuppression. It is also reported to bind fibrinogen and controls the
recruitment of inflammatory cells59. Diversely, low molecular weight HA can also
stimulate the production of proinflammatory cytokines, induce tumor progression,
promote ECM remodeling, and pro-angiogenic60. Despite the research performed
previous decades, there is still little known about all HA’s biological role and the
interplay of different molecular weights which will be beneficial for facilitating the
development of novel-HA therapies.
HA interacts with other cellular receptors other than CD44 in mediating signal
transduction, the formation of a pericellular coating, and receptor-mediated
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internalization mechanism. HA is reported to interact with RHAMM (CD168)61,
HARE62, LYVE-163, and TLR’s59. RHAMM or receptor for HA-mediated cell
motility is involved in tissue repair, modulating signaling pathways, and controlling
internalization of macrophages and fibroblasts. Hyaluronan receptor for
endocytosis (HARE) is mainly involved in clearance of glycosaminoglycans and
is primarily found in liver, lymph nodes, spleen, and the endothelial lining of eye
and kidney. Lymphatic vessel endothelial hyaluronan receptor (LYVE-1) controls
HA-turnover rates, regulation of lymphangiogenesis, and tissue hydration
properties (Summary in figure 4).

Figure 4: Summary of HA cell surface receptors and of the actions that they
control when linked by HA.
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HA presents multiple modifiable chemical groups for chemical modifications
to prolong the half-life and improving properties for preparing new biomaterials
for various medical, cosmetic, pharmaceutical and food applications64,65. Primary
sites for modifications include the abundant hydrophilic hydroxyl groups, carboxyl
groups, and N-acetyl groups on the carbohydrate structure66. Two major
modification strategies include the conjugation and cross-linking of HA.
Conjugation includes the addition of a new molecule to polymer HA for
modification of amphiphilicity, improve drug delivery properties, develop prodrugs, include additional targeting moieties of intended therapeutic outcomes.
Whereas, cross-linking strategies mainly considered for improving rheological,
mechanical, slowing degradation rates, controlled release of pharmaceutical
compounds67, and photophysical properties. Trends in the field of bioconjugate
chemistry also include mixing both conjugation and cross-linking strategies for
developing new scaffolds or biomaterials.
Selected cross-linking agents listed used are hydrazide, 1-ethyl-3-(3-dimethyl
aminopropyl) carbodiimide (EDC), genipin, glutaraldehyde (GTA), divinyl sulfone
(DVS), poly(ethylene glycol) diglycidyl ether (PEGDE) and poly(ethylene glycol)
divinyl sulfone (PEGDVS)68, leading to the formation of HA-based hydrogels for
applications in 3D-cell culture, tumor tissue remodeling, cartilage regeneration,
and drug screening assays69,70. Cross-linking HA directly affects degradation
kinetics which seems to impact in vivo properties of HA for biomedical
purposes71.
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HA for chemically conjugation purpose can be facilitated in aqueous phase
due to its hydrophilic nature and high solubility in water. Click chemistry
syntheses for simple chemo-selective modifications, Diers-Alder cycloaddition,
azide-alkyne cycloadditions, thiol-ene reaction, oxidation, and photo-crosslinked
controlled oxidation alternatives have been used to modify HA effectively72,73,74,75.
Strategies to modify carboxylic groups includes esterification using alkyl halides,
tosylate activation, or use of diazomethane as an activator of carboxyl groups76.
Amidation on carboxylic acid groups includes the use of carbodiimide (i.e., N-(3dimethyl aminopropyl)-N′-ethyl carbodiimide hydrochloride) (EDC). Co-activators
such are N-hydroxy succinimide (NHS) or 1-hydroxy benzotriazole in water, 1,1′carbonyldiimidazole or 2-chloro-1-methyl pyridinium iodide in DMSO and DMF
organic solvents for effective amidation of HA77. Promising methods in increasing
yields could include use of triazine-mediated amidation, using 2-chlorodimethoxy-1,3,5-triazine

or

(4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-

methylmorpholinium (DMTMM)78.
Modifications on hydroxyl groups of HA is carried by formation of epoxides
and bisepoxides by using reagents such as butanediol-diglycidyl ether (BDDE),
epichlorohydrin, and 1,2,7,8-diepoxyoctane in mildly alkaline conditions79.
Esterification of hydroxyl groups of HA can be obtained by reacting octenyl
succinic anhydride, methacrylic anhydride, or acyl-chloride carboxylates80,81,82.
Ether derivatives can be prepared by using divinyl sulfone or ethylene sulfide
reagents. Other non-typical approaches to increase the solubility of HA in organic
solvents include formation of the tetrabutylammonium (TBA) salts for varied multi-
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step synthetic approaches66. Recently, sulfation of hydroxyl groups have gained
substance in past few years due to its unique properties such as slower
degradation rates, promotion of chondrogenesis of human mesenchymal cells83,
binding to different protein stromal cell-derived factor 1-α, SDF-1α for drug
delivery properties84, and binding to Vascular endothelial growth factor 165
(VEGF)85 isoforms for angiogenesis-related disease.
1.6.

Role of sulfated polysaccharides in targeting different receptors in
cancer and infectious diseases
Polysaccharides are an ideal natural source of supplements. As

macromolecular, polysaccharides are derived from the polymerization of multiple
monomeric or monosaccharide containing units linked through O/N-glyosidic
bonds in either linear or branched conformations86. Many polysaccharides have
broad or weak bioactivities due to its structure or physicochemical properties,
conformational states or molecular weight. Regio-selective or full-scale chemical
modifications approaches can be applied to tune chemical, physical, and
biological attributes to alter binding and structural properties. Modifications could
alter molecular weight, substituent groups, and positions, structure impacting
bioactivity87.

Recent

polysaccharides

reports

include

on

various

sulfation88,

modification

phosphorylation89,

approaches

on

methylation90,

carboxymethylation91, acetylation92, deacetylation66, etherification93, alkylation94.
From which, sulfation of glycosaminoglycan presents an attractive hotspot in the
field of polysaccharide research due to the outstanding applications in
pharmaceutical research.
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Sulfated polysaccharides refer to sugar-chains containing polyanionic sulfate
groups on different hydroxyl groups, carboxyl, or amino-terminal groups either
introduced artificially or naturally present supporting a vast array of biological
activities. Composition of sulfated polysaccharides is of keen interest due to its
interesting physicochemical, biomechanical, and biological properties. Naturally
available sulfated polysaccharide broadly includes chondroitin sulfate, iotacarrageenan’s, fucoidan, heparin, keratan, spirulina, and galactans95. The
presence of sulfate group on a polysaccharide sugar backbone renders binding
electrostatically to positively charged biomolecules over a wide pH range (4-12).
Unlike carboxylate polysaccharides, sulfated polysaccharide does not alter pH
and remain stable. It has also been reported using complex computational
modeling algorithms that sulfated polysaccharide possess an open extended
stiffer conformation in solution to minimize the negative charge96.
Given the interest in sulfated polysaccharides, several methods for preparing
sulfated polysaccharides have been developed to understand structure-propertyactivity relationships. Methods include the use of chlorosulfonic acid, sulfuric acid,
sulphamic acid-pyridine, and sulfur-trioxide-pyridine complex87. The most
common and reliable method today employs the use of sulfur-trioxide pyridine
complex in a polysaccharide sulfated synthetic scheme. Newer methodologies
include utilization of microwave reactions, DMAP as catalysts to decrease
reaction time, and chemoenzymatic selective reactions96. Regioselectivity of
sulfation patterns in polysaccharides seem to be influenced mainly due to steric
effects, polarity of O-H bonds in equatorial and axial positions, and acidity of
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hydroxyl group present for substitution. Characterization methods such as NMR
and IR spectroscopy and elemental analysis are widely popular methods for
determining site and degree of sulfation on polysaccharides.
Subtle variations in sulfation patterns can confer a polysaccharide precise
and physiologically relevant interactions with various binding partner proteins
such as cytokines, growth factors, cell-surface proteins, morphogens, plaque
proteins, nuclear proteins, lipid-binding proteins, viral envelope proteins,
enzymes, and extracellular proteins.
Perhaps, the most extensively studied example of a protein-sulfated
polysaccharide interact is the binding of anti-thrombin with heparin and heparin
sulfate due to its pharmacological anti-coagulant relevance97. Structural
information from crystal structure at 2.6-Å resolution revealed the docking site of
heparin pentasaccharide. The active site in proximity was lined with multiple
arginine and lysine residues in a helical conformation effectively binding to
heparin. Heparin is also reported to bind to growth factors such as FGF1, FGF2,
and VEFG. Heparin (Fondaparinux- synthetic analog) is also the only first
clinically approved sulfated polysaccharide since 1935. Limitations of heparin
include shorter half-life, uncontrolled bleeding, an unwanted large number of
binding interactions leading to side-effects.
Other examples include binding of glial cell-derived neurotrophic factor
(GDNF) to sulfated polysaccharides for differentiation of dopaminergic neurons98,
lectin galectin-3 with chondroitin sulfate, dermatan sulfate with heparin cofactor
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II99, and human transforming growth factor-β1 (TGF-β1) with chondroitin
sulfate100.
Similar to heparin, Fucoidan is known to bind to fibroblast growth factor-1 and
2 (FGF-1,2) and similar heparin-binding proteins101. Selectins as a sub-class of
heparin-binding proteins have attracted much attention in the past few years as
an important therapeutic target for delivery of polymers and nanoparticles102.
Reports of fucoidan as a sulfated delivery polysaccharide have been explored for
anti-tumor effects of various chemotherapeutics (MEK and protein-kinase
inhibitors) [Figure 5].

Figure 5: Summary of the recognition of four defined sulfated hyaluronanes by
ten regulatory proteins obtained experimentally by fluorescence polarization.
Affinity ratios of fluorophor-labeled tetra- and hexahyaluronans 15 and 19 (top)
versus the azide-functionalized tetra- and hexahyaluoronans 25 and 26 (bottom)
are represented schematically by arrows. Each of the ten regulatory proteins
analyzed is labeled with a different color, which is also used for the arrows
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representing its affinity ratios. The length and thickness of each arrow correspond
to the ratio of the experimentally determined KD values for this case. A ratio of <
= 10 is illustrated by the length of the arrow and a ratio >10 is represented by the
thickness of the arrow. Each arrow is labeled with a number representing the
determined affinity ratio for this case.
1.7.

Selectins: a new class of receptors
Leukocytes are constantly patrolling the body as “security guards” for sites of

infections or injury as a critical component of both adaptive and innate immune
response. Upon injury or infection, four essential steps are involved in the transfer
of leukocytes, (i) attachment and rolling with the help of selectins, (ii) activation,
(iii) adherence via integrins, and (iv) transendothelial migration via allosteric
structural rearrangements of integrins. Recruitment, trafficking, and extravasation
of leukocytes are orchestrated in a dynamic and coordinated multi-step pattern
by carbohydrate-binding proteins called selectins103.
Selectins belong to a family of type-I cell surface carbohydrate-binding
proteins which are calcium-dependent and are classified in three classes: P-, L-,
E- selectins. All the selectins consist of five domains: an amino-terminal lectin
domain with 50% homology across all selectins, epidermal growth factor domain,
a variable number of complement regulatory-like repeats, and an intracellular tail.
P-selectin (CD62P) is stored within Weibel-Palade bodies of endothelial cells and
are secreted to the surface upon excitation with external factors such as
chemokines, injury, trypsin, oxygen-free radicals104. P-selectin is highly
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expressed on platelets and activated endothelium. E-selectin (CD62E) is present
mainly on endothelial cells and facilitate slow-rolling of leukocyte with weak
binding affinity. L-selectin (CD62L) found on microvilli of most leukocytes are the
majority of leukocyte trafficking at sites of inflammation (Figure 6).

Figure 6: Selectins and their ligands. L-selectin ligands: Glycosylationdependent CAM 1 (GlyCAM-1), Mucosal addressin CAM 1 (MadCAM-1),
leucocyte leukosialin (CD34), P-Selectin-Glycoprotein Ligand 1 (PSGL-1). Eselectin ligands: E-Selectin Ligand 1 (ESL-1) and PSGL-1. P-selectin ligands:
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PSGL-1. Selectins bind their carbohydrate ligands via the c-type lectin domain in
calcium-mediated manner
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The best characterized and physiologically studied ligand for P-selectin is Pselectin glycoprotein ligand-1 (PSGL-1) which is a mucin-like glycoprotein. The
epitope for recognition for P-selectin on PSGL-1 is a tetrasaccharide sialyl Lewisx
(or CD15s)105. Sialyl Lewisx [sLeX] are carbohydrates as O- or N-linked glycans
generally found highly expressed on tumor cells but also is important for homing
malignant cells to bone marrow. sLeX binds to both E- and P-selectin with very
low-affinity of 0.5-0.8 mM affinities. sLeX is post-translationally modified by
glycosylation to add multiple sulfated groups on terminal tyrosine residues near
the N-terminus resulting in a negative charge of -9. The active site in the lectin
domain of P-selectin is lined with multiple lysines, histidine, and arginine residues
resulting in a net positive charge of +9. However, L- and E-selectin have a lesser
degree of basic residues in the active site accruing/leading to a net positive
charge of +4 and neutral charge.
Experimental and theoretical calculations between PSGL-1 and selectins
confirmed a dominance of electrostatics, long-range electrostatics, and saltbridge mediated interactions106. The highest degree of binding was observed for
PSGL-1 was in the order of P-selectin< L-< E-selectin in the decreasing manner.
A report investigating the effects of numerous anions on dendritic polyglycerol
scaffold (carboxylate, bisphosphonates, phosphate, sulfate) confirmed that
sulfate as an anion had the highest binding capacity compared to carboxylate in
binding to P-selectin due to its spatial orientation and highest acidity variable
dictating strong binding capacity to the basic amino acid residues in the P-selectin
active site107.
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Interestingly, the crystal structure presents the fact that the carboxylate of
sialic acid does not interact with the active site confirming the lowest binding of
carboxylate as an anion108. Similar binding positively charged electrostatic
surfaces also support anionic sulfated glycosaminoglycans such as heparin and
fucoidan. Very few hydrophobic interactions were observed between PSGL-1 and
P-selectin at Ser47 and Lys113 residues indicating little to no-effect of
hydrophobic modifications affecting P-selectin binding. In human P-selectin,
arginine85 and histidine114 provide crucial contacts with sulfated PSGL-1;
mechanical perturbations upon P-selectin binding causes a conformational
change allowing more extensive contacts with the post-translationally modified
PSGL-1 leading to high-affinity form (Figure 7). No role of epidermal growth
factor or complement regulatory-like repeats in the structure has been reported
to affect PSGL-1 binding. Majority of the drug design approach has been focused
on studying lectin domain interface for the rational design of small-molecules or
glycomimetic as P-selectin antagonists. Four classes of selectin inhibitors have
been developed and tested in preclinical models: carbohydrate-based selectin
inhibitors; antibodies specific to P-or L-selectin (DREG-55, humanized version of
anti-L-selectin in clinical trial for treatment of multiple trauma); truncated versions
of PSGL-1 immunoglobulin for suitable pharmacokinetic parameters; and smallmolecule

inhibitors

using

in

silico

modeling

approaches

Bimosiamose as selectin inhibitor for pediatric asthma).

(TBC-1269,
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Figure 7: Closer insight into P-selectin active complexed with PSGL-1
highlighting crucial basic amino acids.
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In the past decade, selectins have been implicated in the progression of
cancer109. Tumor cells take advantage of the leukocyte regulation process for its
benefits for extravasation merits particular attention to metastasize to distant
locations. A critical report published in science translational medicine showed that
P-selectin is overexpressed not only at the tumor vascular endothelium but also
on many types of tumors, such as lung, ovarian, lymphoma, and breast cancers,
emphasizing its possible role as a targeting molecule at the tumor cellular level110.
Cancer tumor cells take advantage by increasing its P-selectin expression
forming immune complexes with leukocytes expressing PSGL-1, evading
recognition by macrophages allowing easy access to spread to distant organs.
Various targeting strategies to direct delivery systems to P-selectins have
been explored; researchers demonstrated in vitro cellular drug targeting by lowmolecular-weight fucoidan nanoparticles resulting in increased cell death over
the untargeted, nanoparticle control110. Fucoidan nanoparticle design exploits
selectin expression on tumor cells for delivery of chemotherapeutic drugs in
addition to the EPR effect for increased drug delivery. Several other examples,
researchers have targeted highly aggressive P-selectin positive glioblastoma
cells by using dendritic polyglycerol sulfate for delivery of paclitaxel and antiangiogenic protein thrombospondin-1 for synergistic therapeutic outcomes111;
another group utilized spatiotemporal targeting approach using a dual-ligand
display nanoparticle system for targeting integrin and P-selectin positive MDAMB-231 and 4T1 breast for detection of early metastasis112. This indicates the
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potential of sulfated polysaccharides as nanoparticles which can be developed
to excite discoveries, research, innovation, and translation.
1.8.

Nanoparticles in Biomedical Research and Applications
Research in recent years in the field of nanomaterials have received

considerable attention and seen significant advancements in areas of diagnostics
and the therapeutic realm (Figure 8). Nanoparticles (NPs) with differences in
molecular or atomic compositions are generally considered in size range of 11000 nm113. NPs are defined as solid colloidal mass particles with an increased
surface-to-volume ratio over larger particles providing interest in the field of
targeted drug/imaging agent delivery, tissue engineering, and diagnostic
purposes. Combination of both applications in diagnostic and therapeutic
categories can be commonly termed as “theranostic”114. The exact function and
behavior of these nanosystems will depend on stability, size, shape, scaffold
design, targeting ligands, toxicity profiles, biodistribution, and pharmacokinetic
profiles, for optimized therapeutic outcome. Desirable features of a NPs system
will include; high drug/imaging agent loading for more modalities; targeted
delivery to diseased tissue; long circulation time to limit frequent dosing; nontoxic, highly biocompatible, and biodegradable; controlled interactions with blood
components to prevent degradation; and predictable in vivo profiles115.
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Figure 8: Timeline of nanotechnology-based drug delivery. Here, we highlight
some nanoscale delivery systems that serve as important milestones throughout
the history of drug delivery.
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Taking into account every design parameter of a NPs, size is the most widely
investigated variable that can influence chemical and physical properties
affecting the fate of NPs. Effective interaction of NPs with cellular membranes
are a critical factor in dictating uptake and circulation116. The particle size of less
than 5 nm is more likely to stay in the circulation longer, undergo high renal
clearance; large NPs in the size range of 150nm+ have a higher tendency to
interact more with the reticular endothelial system (hepatocytes, spleen)
decreasing the payload reaching the tumor. A careful optimal balance between
tumor uptake and RES clearance is required to be investigated for different NPs.
Smaller NPs seem to be favorable for accumulating in poorly permeable tumors,
whereas all size ranges seem to accumulate in highly permeable classes of
tumors. The paradigm of the EPR effect has been in many discussions in the field
of nanoparticles as one of the main determinants for passive tumor accumulation.
Researchers determined that the NPs targeting capacity to navigate to interstitial
tumor spaces increased with decrease in size117.
However, most likely, EPR depends on anatomy and permeability
characteristics of the tumor site as “leaky” property of tumor vessels118. Selective
antibodies with high specificities can be conjugated to NPs to seek biomarkers
along with EPR mechanism can accumulate inside tumors leading to better
localization. Nevertheless, conjugating a biologic entity might increase the overall
hydrodynamic size, compromise in terms of targeting ability and size needs to be
considered while designing NPs. However, tumor accumulation of NPs is always
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represented as a fraction of injected dose of NPs, which is usually ranging from
1-10% as the majority end up in MES/RED or cleared by liver and spleen119.
The shape of the NPs system has a significant impact on cellular internalization,
circulation time, and residence time120. Elongated rod shaped-like NPs have
shown to have a higher adhering property compared to spherical particles due to
its higher surface facilitating multivalent interactions with proteins on the cellular
membrane. Spherical nanoparticle have a lower aspect ratio compared to rodlike NPs have shown to be less efficiently taken up by Hela and Caco-2 cells121.
NPs having sharp edges similar to the exoskeleton of a virus have higher
penetration into the endosome and mainly localized in the cytoplasm122. The
elliptical shape has shown to be least favored compared to the spherical and rodlike architecture of NPs for gold NPs. The shape of the NPs has also shown to
influence the corona formation influencing blood circulation and pharmacokinetic
properties123.
Tailoring the nanoparticle surface charge influences different physical,
chemical, and biological characteristics; highly positively charged particles more
likely are cleared quicker and higher incidence of systemic toxicities compared to
negatively charged particles. The charge also is expected to influence RES
uptake, positively charge implicated to have lower uptake by RES. Neutralcharged particles exhibit low sequestration in liver and spleen and high tumor
penetration124. A higher charge density is expected to have more interactions with
charged molecules in the circulation limiting overall tumor penetration, thus
neutral species exhibit slightly higher tumor penetration. Cationic carriers are
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internalized via caveolae-dependent via electrostatic interactions and escape the
endosomes through a mechanism called “proton sponge effect”125.
Self-assembled polymeric NPs have been extensively investigated as drug
carriers to solubilize insoluble drugs/imaging agents to tumors. HA has been
previously used for NPs formulations due to its hydrophilic nature and presence
of abundant conjugatable groups to form discrete hybrid-tunable NPs (Figure
9)126. HA was conjugated to various hydrophobic block-co-polymers to form
amphiphilic systems for delivery of gemcitabine chemotherapeutics127. The
cross-linking strategy was utilized by conjugating 2-(pyridyl dithio)-ethyl of
methacrylate chain to HA to form block-co-polymers128. To improve selective
accumulation in the tumor, these particles were further coated with poly (ethylene
glycol) to improve circulation time and decrease liver uptake129. Photodynamic
therapy applications were explored for HA-based systems by loading doxorubicin
and IR780 dye onto Poly(maleic anhydride-alt-1-octadecene) (PMAO) was
grafted-HA NPs, under near-infrared (NIR) excitation, the photo-dynamic effect
from IR780 was observed along with synergistic cytotoxicity from Dox release to
breast cancer cells130.
HA-based micelles have also been studied for the treatment of ocular
diseases by conjugating hydrophobic alkyl group (hexadodecyl, C16) to loaded
hydrophobic corticosteroids (triamcinolone acetonide and dexamethasone). The
high entrapment efficiency of paclitaxel (93.2%) was observed by increasing
hydrophobicity of HA-based deoxycholic acid NPs, implying tunability of
amphiphilic nature of HA-based nanosystems131.
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Other application of HA includes the coating of positively charged carriers to
facilitate CD44-mediated targeting for increased anti-tumor efficacy. A research
group used positively charged pyridinium group moiety with indocyanine dye to
form micelles with HA. Higher tumor accumulation in SCC-7 model compared to
pyridinium complex indicated HA as an essential polymer for superior targeting
and anti-tumor efficacy132.

Figure 9: Schematic representation of hyaluronic acid (HA) polymeric micelles.
Three possible sites for modification are shown as green circles. In aqueous
solution,

amphiphilic

HA-ligands

can

self-assemble

into

micelles

by

encapsulating drugs or conjugating with drugs. Polymers can be grafted to the
HA backbone. Block-co-polymers and small molecules, such as drugs and
dendrimers, can be conjugated with HA. Positively charged molecules or
polymers can form micelles with HA via electrostatic interactions.
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HA has also shown promise in the field of cancer imaging, especially in the
fluorescence-based image surgery (FIGS). In a research study, Indocyanine
green (ICG) was physically entrapped in hydrophobically-modified [using either
aminopropyl-1-pyrenebutanamide (PBA), aminopropyl-5β-cholanamide (5βCA),
or octadecylamine (ODA) as small hydrophobic molecules], dye loading, optical
properties, and its application in FIGS was evaluated to detect positive MDA-MB231 tumor margins, and local malignant tissues in a xenograft model133. Similar
studies from the same group evaluated the use of cyanine7.5 amine (Cy7.5) in
HA-based nanoformulations to identify promising formulations. NanoICG with
PBA as the hydrophobic ligand and NanoCy7.5 from 100 kDa HA and 30 wt.%
conjugated PBA were identified as lead formulations with outstanding tumor
contrast, and tumor margin detection in immune-competent BALB/c mice bearing
orthotopic 4T1 breast cancer tumors134.
Another group135 demonstrated the use of manganese dioxide (MnO2) NPs
complexed with HA mixing sodium permanganate. HA served as a reducing
agent, surface-coating, and displayed improved colloidal stability, water
dispersibility, and low toxicity. HA-MnO2 effectively detected rat intracranial
glioma with MRI up to 3 days. Highly toxic Gadolinium was doped in HA derived
NPs (HA-GdIO) as MRI contrast agents. HA-GdIO NPs provided a promising role
in targeting CD44-overexpressed atherosclerotic plaques with high magnetic
susceptibility and good biocompatibility136.
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1.9.

Nanoparticles as conjugated and non-conjugated systems in
biomedical applications
Development of fluorescent NPs for both therapeutic and diagnostic value

has emerged from the advantages of EPR effect, drug delivery, and effective
bioconjugation purposes. Fluorescent NPs or polymer dots are broadly classified
into two groups: conjugated NPs and non-conjugated NPs (Figure 10).
Conjugated fluorescent NPs (CF NPs) are a class of promising probes due to
their extensive p-conjugated backbones and delocalized electronic structure137.
CF NPs are derived from p-conjugated small organic dyes which are waterinsoluble as monomeric units forming nanoscale polymeric aggregates. In
principle, such particles can be combined with inorganic particles to form stable
vesicles or micelles as highly-fluorescent dynamic NPs138.
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Figure 10: Representation of polymer dots as Conjugated fluorescent NPs (CF
NPs) and Non-conjugated fluorescent NPs.
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Typical CF NPs have been traditionally synthesized via-classical step-wise
growth

through

Suzuki139,

Heck140,

Sonogashira141,

and

Knoevenagel

polymerization142 using individual starting precursors like acetylene, pphenylene, thiophene, polypyrrole, p-phenylene vinylene, phenylene ethynylene,
and fluorene structures143. Disadvantages of these name-reactions are lack of
control of molecular weight distribution, regioregularity, and strict stoichiometry
requirements144. Applications of the CF NPs are used in electrochemical coating
of charged surfaces for photovoltaics and field-effect transistors. Final products
of CF NPs can be classified into three classes: hydrophobic p-conjugated
polymers, ionic p-conjugated polymers, and solid-state fluorescence emitting
polymers145. CF NPs as ionic versions have charged side chains such as charged
ammonium and negatively charged carboxyl, phosphate, and sulfonate moieties
to provide CF NPs with good water solubility and dispersibility. Ionic groups can
also form binding sites that can interact with oppositely charged biomolecules or
metallic NPs. Solid-state emitting fluorescent polymers (SSEF) have shown to
possess unique photophysical properties that differ from those of typical
fluorescent organic dyes. In the isolated solution state, fluorescence is unusually
quenched as a result of the formation of nonplanar geometries with torsional
freedom, whereas their emission is greatly enhanced by solidification as a result
of restricted torsional motion and minimized quenching interaction146. Thus, they
can maintain bright fluorescence in concentrated or aggregated states without
conventional aggregation-induced fluorescence quenching. Such molecules are
also termed as Aggregation-induced emission dyes (AIE). Examples of SSEF-
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molecules

include

siloles,

cyanostilbene,

tetraphenylethene,

and

distyrylanthracene-based derivatives147,148,149,150.
The most frequently used method to prepare CF NPs is the solvent exchange
technique. In this procedure, a water-miscible solvent is sequentially added to
water with sonication; this causes the polymeric solution to precipitate in small
particles. These particles are then purified by evaporation of organic residues.
This technique is also referred to as nanoprecipitation151. Other less employed
techniques include self-assembly method and emulsion-polymerization152,153.
Upon the formation of CF NPs, strategies have been used to implement the
application for biological systems; researchers prepared low bandgap NIR
fluorescent CF NPs by developing a push–pull conjugated polymer based on a
strong fluorinated thieno [3,4-b]thiophene acceptor via the mini-emulsion
technique154. The NPs were further functionalized with PEGylated (PEG =
polyethylene glycol) surfactant which is beneficial for bioimaging because of a
lower autofluorescence and reduced photon scattering in biological tissues,
resulting in a higher spatial resolution and deeper tissue penetration. However, a
low quantum yield was obtained due to the low-energy bandgap in the NIR region.
Water-solubilizing techniques such as attachment of polar side chains, use of
unreacted carboxyl groups, and stabilization with phospholipids. Surfacefunctionalization also offers bioconjugation of CF NPs to target specific
biomarkers on cancer cells for theranostic purposes155.
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For practical uses, more environmentally friendly engineering of CF NPs needs
to be utilized to avoid potential long-term toxic effects156, immunogenicity, and
metabolism of CF NPs derived from sophisticated synthetic strategies.
Fluorescent polymer dots as non-conjugated polymeric systems (NCPS)
have gained much attention in recent years due to its easy preparation and nontoxic properties. NCPSs do not typically possess a fluorophore which makes it an
exciting kind of fluorescent organic material. Instead, NCPS contain weak subfluorophoric groups such as heteroatom-containing double bonds (C-O, C-N, NO) and single bonds (amino-based groups, C-O), upon suitable immobilization
demonstrate increased fluorescent properties157.
NCPSs are typically prepared by three major types: covalently cross-linked,
supramolecular interactions, and rigidity aggregated. The former two are based
on non-covalent interactions and physical aggregation. The enhancement of
fluorescent properties for NCPS type systems is generally referred to as crosslinked enhanced effect (CEE). It should be noted that CEE is different from AIE,
which is mainly observed in small organic molecules.
Yang and co-workers first demonstrated the Fluorescence mechanism for
NCPSs using hydrothermal treatment to generate covalent linked NCPSs158.
During these processes, the amino groups and saccharide molecules can
undergo dehydration to form the aggregated structures. These aggregated
structures contain abundant C=N Schiff bonds show high fluorescence with
cross-linking. Using branched polyethylene amine as a model non-conjugated
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polymer and small molecule carbon tetrachloride was used to cross-link the NP.
PEI upon cross-linking possessed potential sub-fluorophore units (secondary and
tertiary amines) on suitable immobilization due to cross-linking lead to a decrease
in vibration and rotation.
Furthermore, this decrease in vibration leads to increased blue fluorescence
generation due to a decrease in energy-dependent radiative and non-radiative
transitions. A more red-shifted emission could be obtained if the band-gap
between the two states could be decreased is still under investigation. These
NCPSs possess λex-dependent fluorescence behavior due to the presence of
multiple excited states (presence of plentiful sub-fluorophore groups in the
polymeric NP mesh). The CEE fluorescence effect is also further enhanced in a
“ship-in-a-bottle” approach where a small organic molecule forming subfluorophore units be entrapped in a porous-NP matrix leading to an overall
decrease in vibrations and relaxations.
NCPSs possess interesting optical properties regarding absorption and
fluorescence. The absorption of the NCPSs typically shows strong absorption in
the UV region (230–320 nm), with a tail extending to the visible range. The
maximum peak in the UV region may be ascribed to an n–π* transition of C=N
and C=O bonds or other sub-fluorophore groups. Furthermore, the connected
chemical groups and differences in hybridization derivatives may contribute to
the absorption in the UV/Vis range159. NCPSs possess exceptional physiological
solubility in water (>20 mg/ml) as they are mainly derived from building blocks
which are hydrophilic molecules such as starch, glucose, and saccharides.
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NCPSs is also reported to possess good biocompatibility and low toxicity. Zhu
and co-workers demonstrated160, no in vitro cytotoxicity (cell viability higher than
95%) of different NCPSs with differentiated rat adrenal pheochromocytoma
(PC12) cells by methyl thiazolyl diphenyltetrazolium bromide (MTT) assay. The
toxicity of the NCPDs was also tested in HeLa and 293T cells, and the result
showed that the cell viabilities of both cell types declined by less than 2 % upon
addition of the NCPDs at up to 80 mg mL−1.
Currently, significant progress has been made in the field of functional nonconjugated PDs. The current functionality of the NCPSs is still relatively
monotonous and straightforward; therefore, the design, development, and scaleup of multiple functional NCPSs have become an urgent and indispensable need.
Furthermore, a large number of biodegradable, biocompatible, or bioresorbable
synthetic polymers can be exploited, such as polyols, polyether’s, polyesters,
polylactides, and polyphosphates. The majority of functional NCPDs have only
been used for in vitro biomedical applications, and thus there is still a long way to
go before they are applied to clinical diagnosis and therapy.
2.0. Conclusions
The body of research into polymeric materials for biomedical application
indicates that there is a current and future place for this technology in medicine.
Drug and contrast agent delivery using NPs has already found a place in clinical
medicine for pre-clinical and clinical investigations. Among the many possible
uses, drug and fluorescent contrast agent delivery to solid tumors is of high
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importance. It has already been seen that NP formulations can improve the total
quantity of drug delivered to tumors, and perhaps equally important, they can also
reduce associated toxicities and thereby lessen the already high burden placed
on patients dealing with chemotherapy. Current surgical practices do not
adequately identify the extent of solid tumors, local metastases, and sentinel
lymph nodes, resulting in disease recurrence. It is therefore crucial that new
technologies are developed and moved into the clinic that assists surgeons in the
identification of these tissues.
In the following chapters, we will examine research into polymeric natural
glycosaminoglycan HA, and the application of these systems in studying
interactions with CD44 and P-selectin proteins for applications in image-guided
surgery. We first outline the different approaches using selective regioselective
to study interactions with CD44. Furthermore, narrowing down to one of the
synthetic approaches, we studied interactions with P-selectin. The modified HA
polymers were then formulated to form NPs which were used to deliver imaging
agents

to

tumor

microenvironment

using

dual-targeting

strategy

for

implementation in image-guided surgery. Moreover, we have also demonstrated
interesting use of HA along with different amino acids to form fluorescent organic
nanoparticles (FONPs) for applications in bioimaging and drug delivery.
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CHAPTER II
IMPACT OF STRUCTURALLY MODIFYING HYALURONIC ACID ON CD44
INTERACTION
Abstract: CD44 is a widely-distributed type I transmembrane glycoprotein that
binds hyaluronic acid (HA) in most cell types, including primary tumor cells and
cancer-initiating cells and has roles in cell migration, cell-cell, and cell-matrix
adhesion. HA-derived conjugates and nanoparticles that target the CD44
receptor on cells have been reported for targeted delivery of therapeutics and
imaging agents. Altering crucial interactions of HA with CD44 active sites holds
significant importance in modulating targeting ability of hyaluronic acid to other
cancer types that do not express the CD44 receptor or minimizing the interaction
with CD44+ cells that are not target cells. The approach adopted here was
deacetylation of the N-acetyl group and selective sulfation on the C6-OH on the
HA polymer, which form critical interactions with the CD44 active site. Major
interactions identified by molecular modeling were confirmed to be hydrogen
bonding of the C6-OH with Tyr109 and hydrophobic interaction of the N-acetyl
group with Tyr46, 83 and Ile 92. Modified HA was synthesized and characterized,
and its interactions were assessed by in vitro and molecular modeling
approaches. In vitro techniques included flow cytometry and fluorescence
polarization, while in silico approaches included docking and binding calculations
by MM-PBSA approach. These studies indicated that while both deacetylation
and sulfation of HA individually decrease CD44 interaction, both chemical
modifications are required to minimize interaction with CD44+ cells. The results
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of this study represent the first step to effective retargeting of HA-derived NPs for
imaging and drug delivery.
INTRODUCTION
Hyaluronic acid (HA) is a linear, non-sulfated, and negatively charged
polysaccharide that is comprised of {β1→3} N-acetylglucosamine (GlcNAc) and
{β1→4} glucuronic acid (GlcUA) units. HA, an integral part of the extracellular
matrix (ECM),1–3 contributes to lubrication of joints,4 cell migration5 during
embryonic

morphogenesis,2

cell

adhesion,

tumor

cell

proliferation,2,3,6

metastasis, angiogenesis, tissue regeneration, leukocyte trafficking, and
progression of inflammation and cancer.2,3,7–13 The native ligand for HA is the
transmembrane receptor CD44.14–16 HA binds to the N-terminus of CD44, which
functions as the docking site and is lined by a mixture of primarily basic and
hydrophobic amino acids.17 The CD44 gene contains 20 exons, 10 of which can
be regulated by alternative splicing leading to generation of other splice variants
(variant or ‘v’ exons), which are translated to a polypeptide of molecular weight
80-90 kDa depending on the splice variant.18 Biological functions, such as cell
migration, adhesion, and structural integrity during anti-inflammatory processes,
rely on HA-CD44 interaction.10,11,19–21 The smallest CD44 isoform, CD44
standard (CD44s), is ubiquitously expressed, whereas the variant isoforms are
expressed in a few epithelial tissues and in cancers.10,22,23 The expression of
variants of CD44 is heterogeneous among progression of various tumors. For
example, CD44v10 and v3 are significantly associated with head and neck
squamous cell carcinoma (HNSCC) primary tumors, and were shown to stimulate
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cell growth, proliferation and over-expression of metalloproteinases (MMP),
whereas high expression of CD44v4-9 is observed in other tumors.24–33 HA is
also known to bind to other receptors such as RHAMM and TSG-6. Major
interactions of RHAMM involve association of CD44 for binding34, whereas for
TSG-635 the binding events are controlled by a small 45 amino acid binding
domain, as compared to large 160 amino acid domain in CD44. Recognition of
hyaluronic acid by CD44 regulates various downstream pathways, e.g.
activating/inhibiting phosphorylation of tyrosine kinases, activation of Nanog,
which leads to overexpression of MDR1/P-gp gene, phosphorylation of c-Jun nterminal kinases (JNK), and activation of GSK3β.36–44 The downstream events
are triggered when CD44 recognizes certain key moieties in the hyaluronic acid
polymer chain,38 which include hydrophobic interactions between the N-acetyl
group of HA with the phenyl ring of Tyr83, the side chain of Ile92 and the disulfide
bond between Cys81 and Cys101 of CD44; water-mediated hydrogen bonding
between the carboxylate group of HA with Tyr46 and Arg45 of CD44; hydrogen
bonding between the C6-hydroxy group of HA with Tyr109 of CD44, which serves
to lock HA to the CD44 active site; and hydrogen bonding between the vicinal
diols of HA with guanidine groups of Arg45 and Arg82.17 These interactions are
summarized in Figure 1. Desirable features of CD44-HA binding are the absence
of ionic interactions and strong prevalence of a hydrophobic core.17 The
molecular weight (MW) of HA is also known to play a crucial role in the recognition
and binding to the CD44 protein in the ECM.45
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Figure 1. Interactions of {β1→3} N-acetylglucosamine (GlcNAc) and {β1→4}
glucuronic acid (GlcUA) repeat unit of hyaluronic acid with crucial amino acids in
the murine CD44 active site.
Recently, several groups have attempted to alter the properties of HA by
chemical modification. The modified HA target other proteins and enzymes and
regulate

CD44-independent

biological

processes.

One

such

chemical

modification that has been extensively explored is the sulfation of HA. Sulfated
HA showed selective binding, as measured by surface plasmon resonance
(SPR), for isoform 165a of vascular endothelial growth factor (VEGF165a)46 and
sclerostin, a secreted glycoprotein that has an integral role in bone biology.47
Integration of in silico (molecular docking and dynamics simulations) and in vitro
SPR studies showed that binding to sclerostin was dependent on the degree and
pattern of HA sulfation. Others showed that increased sulfation of HA resulted in
higher binding affinity to TGF-β1 compared with native HA or chondroitin
sulfate.48
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In the current study, HA was rationally modified to investigate the potential to
minimize its interaction with CD44. Our group has previously observed the uptake
of HA-derived nanoparticles (NPs) into CD44-expressing tumors and organs, e.g.
liver and speen.49–51 Liver cells express stabilin-2 (sub-family of CD44) and
spleen cells have high expression of CD44.52 Similar results were observed by
Lin et al.53, where HA-IR-780-based nanosystems accumulated largely in liver
and spleen. HA-functionalized glycyrrhetinic acid nanoparticles accumulate in
major CD44 clearance organs–liver and spleen54. This demands new
approaches to design polymers by precisely tuning their structure to achieve
maximum tumor accumulation by reducing CD44 interactions to non-target
organs.
Ultimately, we postulate that NPs derived from structurally-modified HA could
have decreased uptake in liver and spleen and/or could be retargeted by
conjugation of other targeting ligands to specific receptors with the end goal of
increasing accumulation of NPs in tumor. By chemically modifying HA, a wide
spectrum of binding partners can be exploited in rationally designing a robust
drug/dye delivery system for enhanced tumor recognition. The investigation
reported here studies HA-CD44 binding after HA deacetylation, sulfation, and a
combination thereof. We hypothesized that deacetylating the HA backbone as
one modification, selectively sulfating the C6-OH as a second modification, and
incorporation of both deacetylation and sulfation as a third modification, would
decrease the binding of these modified derivatives of HA to CD44. Interactions
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of the modified HA with CD44 were measured using flow cytometry, fluorescence
polarization, and in silico approaches.
Materials and Methods
Sodium hyaluronate, 10 kDa, was purchased from Lifecore Biomedical
(Chaska, MN). Tetrabutylammonium (TBA) hydroxide, DOWEX 50WX8-400 ion
exchange resin, sulfur trioxide pyridine complex (SO3-pyridine 98%), hydrazine,
hydrazine sulfate, N-(3-Dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride
(EDC), N-hydroxysuccinimide (NHS) and fetal bovine serum (FBS) were
purchased from Sigma-Aldrich (St. Louis. MO). All water was purified with
Barnstead™ Nanopure™ Diamond system (Thermo Scientific; Waltham, MN).
Methanol, N,N-dimethylformamide (DMF), 96-well tissue culture plates (Falcon),
12-well tissue culture plates and dialysis tubing (MWCO = 3500) were purchased
from Fisher Scientific (Pittsburgh, PA). Ethanol was purchased from the WarnerGraham Company (Cockeysville, MD). Recombinant human CD44-Fc Tag
(HPLC–verified) was purchased from Acrobiosystems. Ninhydrin reagent and
hydridantin dehydrate 96% and fluoresceinamine isomer I, 99% were purchased
from ACROS Organics and 2-methoxyethyl acetate was obtained from TCI
America. Anti-CD44 antibody was purchased from BD Pharmigen BD
Biosciences. NMR was performed on a 500 MHz Bruker or 600 MHz Varian
system using a 5 mm probe at room temperature. Deuterated water (D2O, 99.9%
D) was purchased from Cambridge Isotope Laboratories. FTIR measurements
were performed on Nicolet IR200 FT-IR instrument using single-reflection ZnSe
ATR crystal. Penicillin/streptomycin (100X solution) was purchased from
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Corning. Cell lines (PC-3, MDA-MB-231, RKO and LNCaP cells) were obtained
from American Type Culture Collection (Manassas, VA) and were grown in RPMI1640 (HyClone, GE Healthcare Life Sciences) with 10% fetal bovine serum and
1% penicillin/streptomycin (P/S).
Preparation of modified HA derivatives
Modifications to HA were synthesized based on methods described in the
literature46,55 with slight modifications as described below (Scheme 1).

Scheme 1. Synthesis of deacetylated, sulfated, and deacetylated and sulfated
HA. i: ion exchange with TBA in H2O; ii: hydrazine, hydrazine sulfate, DMF; and
iii: sulfur trioxide pyridine, DMF.
Synthesis of TBA salt of hyaluronic acid (HA-TBA). Sodium hyaluronate (10
kDa, 250 mg) was dissolved in 100 ml ultrapure water, which was mixed with 5 g
of DOWEX 50WX8-400 ion- exchange resin to allow the substitution of sodium
ions with TBA. This mixture was stirred for 6-8 h for the effective exchange
process. The reaction mixture was then filtered through a 0.45 µm membrane
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filter paper obtained from Millipore. This solution was then lyophilized to yield a
white powder with a yield of 90% (HA-TBA).
Synthesis of deacetylated HA-TBA (deHA-TBA).

HA-TBA (200 mg) was

dissolved in a three-neck round bottom flask with 20 mL DMF under argon flow
at room temperature (rt) to aid the formation of a homogenous mixture. Hydrazine
(20 mL) and hydrazine sulfate (200 mg) were added to the mixture and the
reaction was allowed to proceed for 8 h under an atmosphere of argon at 100°C.
After the reaction was complete, the mixture was cooled to rt and the pH was
adjusted to 10 using 4.0 M aqueous NaOH. The mixture was dissolved in 100 mL
of 1:1 acetone:water, which was then extensively dialyzed (MWCO = 3500 Da,
Spectrum Laboratories) against 1:1 methanol:water for 24 h, followed by 1:1
ethanol:water for 24 h with 4 changes and finally 8 changes of water over 72 h to
remove unreacted TBA. The material obtained had a yield of 24% and was then
lyophilized and stored at -20°C.
Selective sulfation of hyaluronic acid at C6 position (sHA). HA-TBA (200 mg)
was dissolved in a three-neck round bottom flask with 20 mL DMF under argon
for 15 min. Sulfur trioxide pyridine complex (0.325 g) was dissolved in 4 mL of
DMF and added dropwise to the reaction mixture. The temperature was
maintained at rt for 40 min, and then the reaction was quenched by adding 20 mL
of ultrapure water. Acetone was added to the reaction mixture to precipitate the
product, which was then filtered and washed with acetone and water. The product
was dissolved in water and dialyzed against 1:1 ethanol:water for 24 h with 4
changes followed by 48 h of ultrapure water with 8 changes. This solution was
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then lyophilized yielding an off-white solid with 82% yield that was stored at 20°C.
Synthesis of deacetylated and sulfated hyaluronic acid (s-deHA). Sulfated
HA-TBA, as prepared above, was utilized for the preparation of deacetylated and
sulfated hyaluronic acid. Sulfated hyaluronic acid-TBA compound (200 mg) was
dissolved in 20 mL of DMF under argon for 15 min in a three-neck round bottom
flask. Hydrazine (20 mL) and hydrazine sulfate (200 mg) were added to the
reaction under argon. The reaction mixture was stirred for 8 h at 100°C. It was
then allowed to cool to rt and its pH was adjusted to 10 using 4.0 M NaOH. The
mixture was then dissolved and dialyzed as described for deHA-TBA above,
lyophilized, and stored at -20°C (yield = 34%).
Deacetylation quantification. The colorimetric ninhydrin assay was used to
quantify the primary amine produced by deacetylation of the N-¬acetyl-Dglucosamine monosaccharide. Standard solution (0.1 mg/mL) of glucosamine
was used to build the standard curve in acetate buffer (0.5 mL; pH 5.5; 4 M).
deHA (0.5 mg) and s-deHA (0.5 mg) were used for the assay. The ninhydrin
reagent was prepared by mixing 1 g ninhydrin, 0.12 g hydridantin, 23 mL of 2methoxyethyl acetate with 12.8 mL of 4 N acetate buffer. The total volume of the
sample was 2 mL, and this solution was heated in a boiling water bath for 15 min.
The reaction mixture was cooled subsequently to rt followed by measuring the
absorbance at 570 nm. Absorption and spectra were recorded on Evolution 220
spectrophotometer (Thermo Scientific) in quartz cells with the optical path length
of 10.0 mm at 25°C.
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Synthesis of hyaluronic acid conjugate with fluoresceinamine (HA-FITC).
Sodium hyaluronate (90-95 mg, Mn = 10-20 kDa) was dissolved in 20 mL of
ultrapure water in a 50 mL round bottom flask. Fluoresceinamine (8 mol %) was
dissolved in 10 mL DMSO under constant stirring. NHS and EDC, 96-132 mmol
(10x molar excess to fluoresceinamine) were dissolved into HA solution and
stirred for 30 mins to allow activation of carboxylic groups on HA. The
fluoresceinamine DMSO solution was then added dropwise to HA solution under
constant stirring. The reaction mixture was stirred for 24 h at rt, wrapped in foil to
prevent light exposure. The reaction mixture was then dialyzed against 1:1
ethanol:water for 48 h with 4 changes followed by water alone for 72 h with 8
changes. The product was lyophilized and stored at -20°C with a yield of 68%.
Flow cytometry analysis for binding assays
A cellular binding assay was performed using HA-FITC as the competing probe.
MDA-MB-231, PC-3, RKO and LNCaP cells, approximately 90,000 cells/well,
were seeded in a 12-well plate. The cells were pre-incubated with sHA, deHA,
s-deHA and HA (200 µM) for 1 h at rt with constant shaking. HA-FITC (20 µg/mL)
was added to the mixture for 1 h under constant shaking in the dark as the
competing ligand to allow for displacement of the unlabeled sample. Cells
incubated with unlabeled HA served as the negative control, whereas cells
incubated with HA-FITC alone served as the positive control. After incubation,
the cells were diluted to 300 µL with PBS in FACS tubes. A FACS LSRII-green
flow cytometer (BD) was used for all flow cytometry measurements. A total of
10,000 gated events were acquired per sample and the mean fluorescence
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intensity was plotted in a histogram-based graphical representation. Each data
point is representative of the mean of three independent measurements on the
flow cytometer. Data were analyzed with FlowJo (Tree Star) software.
Fluorescence polarization assay
Fluorescence polarization measurements were performed in a 384-well lowvolume black round-bottom polystyrene NBS microplate (Corning) using a
Spectromax M5 plate reader (Molecular Devices, Sunnyvale, CA, USA).
Polarization values are reported as millipolarization units (mP). The fluorescent
probe, HA-FITC, synthesized above and rhCD44-Fc were dissolved in 1X PBS.
For direct binding assay between the fluorescent probe and the CD44 protein, 1
µL of 50 nM fluorescent probe and 10 µL of solution with increasing concentration
of recombinant CD44 protein (130 nM-72 µM) in PBS were transferred to the
microplate wells. The final volume of the reaction mixture was 11 µL in each well,
and all measurements were performed in triplicate. The microplate was shaken
for 5 min in the dark at rt before being read by the plate reader (lex = 489 nm;
lem = 538 nm). Estimation of binding of modified HA derivatives was carried out
using a competitive binding assay. To each well in the 384-well plate, 10 µl of
23.4 µM recombinant CD44 was added along with 1 µl of increasing
concentration of unlabeled HA derivatives (64 nM - 1000 µM) and 1 µl of
fluorescent probe (HA-FITC, 50 nM). The total volume of the reaction mixture was
12 µL in each well. Fluorescence measurements were made after a 15 min
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incubation. The data was fitted and IC50 values were determined using a nonlinear least square fit to a single site binding model (Graphpad v7.0).
Molecular docking of hyaluronic acid derivatives
The X-ray diffraction crystal structure of mouse CD44 hyaluronan-binding
domain was obtained from Protein Data Bank (PDB ID: 4MRD).17 There is
similarity in binding of HA between the murine and human CD44 active site, which
is conserved.17,56 Molecular docking was performed to gain deeper insight into
the interaction of modified hyaluronic acid derivatives compared to native
hyaluronic acid. The protein structure was cleaned by removing water molecules
and other inorganic ions/atoms. The HA ligand consisting of 12 units was
prepared in Maestro molecular modelling software (Schrodinger). Docking
studies were performed using Auto-DockTools (AutoDock Vina).57 The grid box
of dimensions 40 Å X 40 Å X 40 Å was generated with a 0.375 Å spacing to
perform docking. AutoDock Tools were used to add Gasteiger charges and polar
hydrogens to CD44 and modified hyaluronic acid derivatives. The structures were
saved in .pdbqt file format. These systems were loaded in the graphic user panel
and the grid pane, grid box, and the box dimensions were set accordingly to
completely occupy the entire ligand-protein surface to perform docking using
AutoDock vina software.58 10 runs were performed for statistical analysis on the
obtained docking results. Docking was also performed using SwissDock
(http://swissdock.vital-it.ch/),59,60 provided as a free web service. The ligands
were docked to the desired protein structures by using suitable docking
parameters allowing the online web service to produce docking results using
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CHARMM energies.60 Similar grid size box dimensions used in AutoDock were
used for SwissDock. The docked ligand file was visualized with the protein using
UCSF Chimera 1.4.61.
Statistical Analysis
Analysis of competitive binding flow cytometry, fluorescence polarization, and
molecular docking were performed with one-way ANOVA with Tukey multiple
comparisons test, Student’s t test, and non-linear least squares fit to a single site
binding model.
All statistical analysis was done in Prism 7.0 (GraphPad Software; La Jolla, CA)
and Microsoft Excel.
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Results and Discussion
Synthesis and characterization of modified hyaluronic acid derivatives
(deHA, sHA and s-deHA)
Deacetylated, sulfated, and deacetylated sulfated HA derivatives were
prepared according to Scheme 1 using previously reported methods with slight
modifications. Based on their importance for CD44-HA binding,17 the N-acetyl
and the C6-OH moieties were chosen for synthetic modifications. We synthesized
deacetylated, sulfated, and deacetylated sulfated derivatives of HA of molecular
weight 10 kDa by controlling the amount of hydrazine and hydrazine sulfate for
deacetylation reaction and molar ratios of sulfur trioxide-pyridine complex per
repeat units of HA for selective sulfation reaction. The N-acetyl group was
deacetylated using the hydrazine/hydrazine sulfate mixture following the WolffKishner reaction under reflux conditions under an atmosphere of argon, cleaving
the acetyl group with the initial evolution of gas to produce the amino group during
the reaction. The degree of deacetylation of HA changed with the reaction times
from 4 to 8 h. The 8 h reaction time was close to 100% deacetylation with
complete absence of N-acetyl peak in the corresponding 1H NMR spectra (2-2.2
ppm) as seen in Figure S5 with reference to 1H and

13

C NMR spectra of HA in

Figures S6-7. The deacetylation reaction by hydrazinolysis has been reported to
cause a reduction in overall molecular weight62 due to C-5 epimerization and βelimination at the C-4 position leading to breakdown of the glycosidic bonds.63
We observed a lower yield of deacetylated HA presumably due to the above
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explanation. At the reaction temperature, the deacetylating agents, hydrazine and
hydrazine sulfate, convert the free carboxylic group to carboxylic hydrazides. For
this reason, the TBA salt was synthesized to avoid generation of side products.
Ninhydrin colorimetric assay was used to quantify the degree of deacetylation of
HA. The ninhydrin reaction is specific to the primary amino group generated
during deacetylation reaction producing a distinct purple violet color which was
quantified by absorption spectroscopy. 1H-NMR was also used to assess the
degree of deacetylation, where one repeat unit of native HA bears 3 methyl
protons for every 2 anomeric protons leading to the theoretical integral ratio
between the two of 3:2, respectively. Using this ratio equation,64 the degree of
deacetylation was calculated to be 82.6 and 88% for deHA and s-deHA obtained
from Ninhydrin assay standard curve. Selective sulfation of HA was controlled by
using 3:1 molar ratio of sulfur trioxide-pyridine complex to repeat units of HA.
Major sulfation sites on HA are the primary hydroxyl group being the most
reactive, while other (secondary) hydroxyl groups are less susceptible to the
attack of the sulfating nucleophile moiety due to steric hindrance and spatial
orientation of these groups on HA. 1H and

13

C NMR analysis was performed on

sHA and s-deHA to confirm the sulfation of HA (Figure 2a-d). The reactive center
C-6 OH linked to CH2 exhibited a downward shift to 3.55 ppm due to the
increased electron withdrawing caused by the sulfate group. Absence of
additional peaks between 3.9-4.4 confirmed no side products at positions C-2’,
C-3’ and C-4’, indicating selective sulfation of the C-6 OH (Figures S1-S4). The
FTIR data in Figure 2 demonstrates the peaks for vibrations of C-O-S and S=O

68
in the range of 800 and 1290 cm-1, indicating the presence of sulfate moieties in
sHA and s-deHA. These results were also confirmed by elemental analysis for
sulfate content (Table S1).

13

C NMR spectra confirmed that HA was sulfated at

C6 position by the shift of the C-6 peak from 61.9 to 68 ppm with complete
disappearance of the former shown in Figure S3. The surface charge for the
modified polymers was assessed using zeta potential to further support the
results from colorimetric assay and NMR spectroscopy. Deacetylation was
responsible for introducing positive charges in the polymer, thereby shifting the
zeta potential of highly negative HA to near neutral values. The s-deHA had a
zeta potential of -6 mV, indicating counter balancing effects of both positive and
negative charges induced due to deacetylation and sulfation (Figure 3). At the
same time, sulfation lead to further negative charge.
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Figure 2 and 3: FTIR spectra of native and modified 10 kDa HA, Zeta potential
of HA and modified HA.
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Figure 2a: 13C NMR spectra of sulfated HA (sHA)
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Figure 2b: 1H NMR of sulfated HA
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Figure 2d: 1H NMR of deacetylated HA (deHA)
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Flow cytometry analysis of binding of modified HA polymers to CD44
The in vitro binding affinity of modified hyaluronic acid polymers was studied
using CD44-expressing cell lines (PC-3, MDA-MB-231 and RKO) and a CD44negative cell line (LNCaP). PC-3 prostate, MDA-MB-231 breast, RKO colon
cancer cells overexpress CD44 on their surface. The cell lines were first
confirmed for CD44 expression using a PE-labelled anti-CD44 antibody. Analysis
confirmed that the LNCaP prostate cancer cells did not express the CD44
receptor, while the other cell lines had pronounced CD44 expression (Figure 4).
To study the interactions of modified HA with CD44+ and CD44- cell lines we
used an assay based on the concept of competitive binding, where the modified
HA polymers were initially pre-incubated with the cells for 1 h to allow their binding
to the CD44 receptor on the cell surface. This was followed by incubation with
HA-FITC for another 1 h to allow competition of the native ligand with the modified
HA for the CD44 receptor. Cell staining was then analyzed using the FITC gate
to allow acquisition of FITC fluorescence intensity over 10,000 events. In all
CD44+ cell lines, HA-FITC effectively displaced the modified polymers, yielding a
higher fluorescence intensity compared to the cells incubated with HA. When the
cells were incubated with native unlabeled HA, the displacement by the HA-FITC
was not effective compared to the modified HA polymers, indicating that
unlabeled HA had a higher binding affinity than modified HA. To confirm the
findings, the assay was performed using the CD44- cell line, LNCaP. Here, the
overall fluorescence intensity for all HA derivatives was significantly lower
compared to CD44+ cell lines, demonstrating little or no affinity for CD44- cells.
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Results are reported as both fluorescence intensity and fluorescence intensity for
the modified HA polymers for individual cell lines (Figure 5). Fluorescence index
(FI) values were calculated using the following equation, where MFI is mean
fluorescence intensity:
𝑀𝐹𝐼 = (𝑀𝐹𝐼'()*+, − 𝑀𝐹𝐼/,0(123, 45/165+ )/(𝑀𝐹𝐼*5'2123, 45/165+ − 𝑀𝐹𝐼/,0(123, 45/165+ )
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Figure 4. CD44 expression studies. Flow-cytometry histograms showing the
expression of CD44 receptor (left plot) and the ability for HA to block HA-FITC
binding (right plot) of CD44+ (A) MDA-MB-231, (B) RKO, (C) PC-3 and CD44- (D)
LNCaP cell lines. HA competitively inhibited HA-FITC binding in CD44+ cell lines,
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while CD44- cell lines had lower HA-FITC signal and no difference in signal after
competition with HA.

Figure 5. Competition binding assay using flow cytometry analysis. Binding of
HA-FITC (20 µg/ml) for 1 hr in the presence of modified HA and native HA
determined in (A) MDA-MB-231, (B) RKO, (C) PC-3, and (D) LNCaP cancer cell
lines. Negative control comprised of incubation of cells with unlabeled HA while
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positive control cells were incubated only with HA-FITC. The left column indicates
fluorescence intensities obtained after competition binding of modified HA
polymers during flow analysis, while the right column indicates the normalized
fluorescence intensities based on the obtained negative and positive
fluorescence intensities. Data are shown as mean ± S.D., * p<0.05, ** p<0.01, ***
p<0.001; One-way ANOVA with Tukey multiple comparisons test.
Interaction of modified HA polymers with CD44 recombinant protein
studied by fluorescence polarization
The interactions between CD44 and modified HA polymers were studied
using fluorescence polarization via a competitive binding assay method.
Fluorescence polarization (FP) is a powerful technique used to study
biomolecular interactions. FP assays require relatively small amounts of
expensive reagents as they have been miniaturized to 384 and 1536 well formats.
FP values in an assay are dependent on the rotational rate which correlates with
the molecular weight of the fluorescent species. A low FP value indicates the
presence of unbound fluorescent probe, which rotates rapidly, resulting in
depolarization of light, whereas binding of the fluorescent probe to a high
molecular weight protein or bio-macromolecule rotates the complex slowly,
thereby yielding higher FP values. Fluorescence polarization is usually recorded
in mP (millipolarization units). The advantage of using FP is that the protein and
the fluorescent probe are not immobilized on the surface, therefore allowing no
interference between the probe and the binding site domain of the protein.
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The binding affinity of HA for CD44 was determined by titrating HA-FITC
probe (50 nM) with CD44 (130 nM - 72 µM) (Figure 6A). A dose-dependent
increase in the FP values was observed in HA-CD44 binding while no such effect
was observed with fluorescein as a probe, which is indicative of CD44-HA
binding. Binding affinity (Kd) of HA-FITC was determined to be 21 µM using
nonlinear least square fitting to a single-site binding model. This is consistent with
studies reported in literature, where the binding affinity (Kd) of 24.6 µM was
determined by isothermal titration calorimetry16 and SPR.65,66.
To evaluate the effect of HA modifications on CD44 binding, we conducted a
series of competition assays. In each assay, a constant mixture of the HA-FITC
and CD44 was titrated with modified HA. The IC50 values of unlabeled modified
HA were determined using nonlinear least square fitting to a single-site binding
model. The data shows that individual modifications (deacetylation and sulfation)
indeed reduce binding to CD44 (Figure 6B). Incorporating both modifications to
HA results in reduced binding to CD44 compared to single modifications; specific
values could not be obtained as the slopes were very broad for double modified
HA. Based on these results we suggest that the secondary amino and sulfo
groups on modified HA reduce the affinity of HA for CD44.
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Figure 6: (A) Binding curve isotherm of HA-FITC (50 nM) to CD44-Fc protein
(130 nM-72 µM). Kd value obtained for the conjugate = 21 µM. Values are
expressed as mean ± s.d of n=3 (B) Effect of increasing concentration of
unlabeled derivatives of HA (64nM- 1000µM) and constant CD44 concentration
of 23.4 µM competing with pre-incubated HA-FITC (50 nM).
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Molecular docking
Docking studies and binding energy calculations were used to predict the
recognition of modified HA derivatives to CD44 receptor. Docking was carried out
using modified HA derivatives and native HA with CD44 protein. Docking
energies were obtained using Swissdock and Autodock docking software
packages and compared to observe a trend in decrease of binding energies
based on the modifications in the HA structure. The modified HA derivatives,
deacetylated and sulphated HA, had lower binding energies of -8.7 kcal/mol and
-7.6 kcal/mol, respectively, compared to -13.2 kcal/mol for native HA. This implies
that the lower binding energies after the N-acetyl and the C6-OH group were
chemically modified caused the differences in docking energies due to repulsive
interactions of the amino group interactions and sulfo group. The repulsive
interaction hindered locking of the HA structure on the active site of the protein,
as indicated in Figure 7 and Table 1, consistent with AutoDock and SwissDock
calculations. s-deHA had the lowest binding energy compared to single
modifications. This implies that both modifications combined to make interaction
with CD44 least favorable. Findings from FP indicate the order of affinity HA >
deHA > sHA > s-deHA, whereas from molecular docking study we observe the
order of HA > sHA > deHA > s-deHA. Both modifications decrease binding to
CD44. It was observed that only one disaccharide unit is responsible for
interaction with the active site, as illustrated in Figure 1. The described
modifications on the disaccharide were observed to interfere with the major
interactions which are key determining factors for HA and CD44 binding. Such
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structural changes, being introduced with the same substitution ratio, should have
similar effect regardless of the MW of the polymer, as only its small fragment is
responsible for the interaction. This provided the rationale of exploring only one
lower molecular weight (10 kDa) of hyaluronic acid. In contrast, different
substitutions ratios will have different effect on the binding affinity even with the
polymer backbone of the same molecular weight. However, an important
consideration should be kept in mind that hyaluronic acid belongs to family of
natural carbohydrates67, where controlling the exact molecular weight and
chemical substitution ratio is extremely challenging. Even with precise
stoichiometric substitution ratio under control, it will be virtually impossible to
control such modifications site-by-site. This will lead to the possibility for the less
(or completely unmodified) fragments of the polymer to determine the interaction
with CD44.

Figure 7. Docking energy calculated by Autodock software of HA and modified
HA derivatives with CD44 indicate that each of the modifications had a lower
binding energy compared to native HA with CD44. Graphs show mean ± SD
(n=10), **** p < 0.0001; One-way ANOVA with Tukey multiple comparisons test.
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Conclusions
The reported study was focused on evaluating the effects of chemical
modifications of hyaluronic acid on its binding affinity to standard CD44
glycoprotein receptor. Chemically modified HA was previously shown to
selectively bind various proteins, e.g. TIMP-3, VEGF165a, FGF-2, sclerotin, and
hBMP-4. Modifying HA structure, which alters CD44 interactions, could also
potentially affect other receptors such as RHAMM and TSG-6, since these
interactions are exquisitely sensitive to compromising the selectivity by altering
the overall chemical structure. However, modifications such as deacetylation and
sulfation of HA have not been thoroughly evaluated for their influence on CD44
binding. Here we have described a novel methodology for tuning HA properties
to control its binding to CD44. Our in vitro and theoretical modeling studies have
revealed good correlation of reduced binding with chemical modifications on HA.
Future studies will evaluate higher molecular weight HA, since recognition of
different molecular weight of HA and downstream activation pathways are
different for the polymers of various MW.68,45,69,70 Further, we will investigate in
vivo the role of HA modification on overall biodistribution, tumor accumulation,
and pharmacokinetic profiles by developing nanosystems based on polymers
designed to increase payload of imaging agents/drugs to tumors.
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CHAPTER III:
MODULATING TARGETING PROPERTIES OF HYALURONIC ACID FOR
DELIVERY OF IMAGING AGENTS TO TUMOR MICROENVIRONMENT

Abstract
Many targeting strategies can be employed to direct nanoparticles to tumors
for imaging and therapy. However, tumors display a dynamic, heterogeneous
microenvironment that undergoes spatiotemporal changes, including the
expression of targetable cell-surface biomarkers. Here, we develop a
nanoparticle system to effectively target two receptors overexpressed in the
microenvironment

of

aggressive

tumors.

Hyaluronic

acid

(HA)

was

regioselectively modified using multi-step synthetic approach to alter binding
specificities for CD44 and P-selectin for improving targetability. The dualtargeting strategy utilizes sulfate modifications that target P-selectin, in addition
to native targeting of CD44, which exploits spatiotemporal alterations in the
expression patterns of these two receptors in cancer sites. Using biophysical
characterization,

e.g.

fluorescence

polarization;

in

vitro

evaluation

by

CRISPR/Cas9 system and flow cytometry binding studies; and in vivo infrared
imaging, we demonstrate that modified HA nanoparticles effectively target
tumors, offering higher specificity over conventional HA strategies. The uptake of
sulfated HA nanoparticles is higher compared to non-sulfated HANPs as
assessed using fluorescence image-guided surgery and whole-animal imaging
systems.
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Introduction
Targeted delivery systems are devised to provide safe, efficacious, and
focused delivery of therapeutic agents or imaging probes at intended sites1.
Common delivery systems include multi-lamellar liposomes2, dendrimers3,
quantum dots4, polymer dots5,6, carbon dots7, antibody-drug conjugates8, protein
conjugates9, nanoparticles, and others delivery modalities. Each of the delivery
systems has its unique ability which can be exploited for delivery of drugs/imaging
agents. Designing an appropriate delivery system is contingent on the diverse
properties such as binding affinities, shape, size, physiochemical and
photophysical characteristics, uptake, stability, corona forming proteins,
biodistribution, and pharmacokinetics10,11,12,13. These parameters primarily
govern the biological fate of delivery systems depending on the chemical charge
tunability, surface charge for cell uptake, cellular internalization, and cellular
protein targetability. Therefore, no delivery system is perfect for fulfilling all
targeting goals, but with rational approach targeting properties of a carrier can be
modulated.
The clinical potential of nanomedicine is currently being exploited in terms
of targeting of various cancer types for positive therapeutic outcome14. Usually,
nanoparticles passively target the tumor microenvironment by enhanced
permeation retention (EPR) effect15. Targeting strategies for nanoparticles have
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been improved by adoption of active targeting by conjugating peptides16, small
molecules, or antibodies17 that target specific cell surface markers that are
overexpressed on cancer cells compared to normal healthy tissues. However,
the tumor microenvironment presents a heterogeneous and dynamic population
of multiple targetable cell-surface proteins that are over-expressed, such as,
CD4418, P-selectin19, amino acid transporters20, folate binding proteins21, EGF,
HER2, integrins, CXCR4, FGF, Tetraspanins, Bombesin22.
In this work, we investigate a novel strategy of targeting two upregulated
cell surface markers (CD44 and P-selectin) by regio-selective chemical
modifications on hyaluronic acid. P-selectin, which is an inflammatory cell
adhesion protein, is responsible for recruiting leukocytes to inflamed/infectious
sites by binding to P-selectin glycoprotein-1 (PSGL-1) allowing adhesion and
extravasation23. Cancer cells take advantage of this machinery to evade
recognition by the macrophages24 by expressing P-selectin on the surface which
is induced by the harsh tumor microenvironment (endogenous cytokines, external
stimuli, exposure to thrombin, and oxygen free radicals). Previously, high Pselectin expression was reported in breast, pancreatic, liver, ovarian, and lung
cancers19. It was used as a possible target for delivery of mitogen-activated
kinase protein kinase inhibitor using fucosylated nanoparticles specific to Pselectin19. Mizrachi et al.25 exploited P-selectin as a target to deliver tumorspecific PI3K inhibitors via fucoidan nanoparticles to head and neck cancer tumor
model. Additional reports have discussed delivering paclitaxel via dendritic
polyglycerol sulfate to P-selective positive glioblastoma cells26.
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Active targeting has been widely implemented to increase cellular
internalization of delivery systems for improving therapeutic/diagnostic effects27.
CD44 and P-selectin have demonstrated increased expression in breast,
pancreatic, liver, ovarian, lung cancers. In addition, poor patient survival has been
reported with tumors co-expressing both receptor families28 demonstrating the
need for dual-targeted design of nanosystems. Further development of dual
targeting was addressed using a DPPC cholesterol liposomal nanoparticle
specific towards P-selectin and avb3 integrins for detection of breast cancer
metastasis29. This suggested that P-selectin is a target with strong potential for
cancer therapy.
Previously, we reported modifications of several functional groups of
hyaluronic acid by deacetylation and sulfation, which resulted in a decrease, but
not abolishment of CD44 binding30. Based on the findings that sulfation is an
essential modification on hyaluronic acid, we hypothesized that modulating
sulfation patterns on hyaluronic acid might potentially influence binding to both
P-selectin and CD44. This may be used for applications in near-infrared imageguided surgery to improve tumor detection and surgical resection. In this study,
we harnessed the targeting potential of sulfated HA towards P-selectin and CD44
in a proof-of-concept model using a pancreatic cancer cell line.
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Graphical abstract
Illustration of the targeting recognition by modulated hyaluronic acid nanoparticle
targeting to both CD44 and P-selectin via dual-delivery of imaging agents for
image-guided surgery.
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2. Material and Methods
Sodium hyaluronate, 10 and 100 kDa, was purchased from Lifecore
Biomedical (Chaska, MN). All water was purified with Barnsteadt Nanopure
Diamond system (Thermo Scientific, Waltham, MN). Tetrabutylammonium (TBA)
hydroxide, DOWEX 50WX8-400 ion exchange resin, sulfur trioxide pyridine
complex (SO3-pyridine 98%), N-(3- dimethylaminopropyl)-N-ethylcarbodiimide
hydrochloride (EDC), N-hydroxysuccinimide (NHS), fetal bovine serum (FBS),
and 1-pyrenebutyric acid were purchased from Sigma-Aldrich (St. Louis. MO).
Cy7.5-amine was obtained from Lumiprobe Corporation (Hallandale Beach, FL).
IRDye® 800CW amine was purchased from LI-COR Biosciences (Lincoln, NE).
Desalting PD10 columns, dialysis membranes (3,500 MWCO and 6,000–8,000
MWCO), Nunc™ Glass Bottom Dishes (12 mm), Nunc Lab-Tek II Chamber Slide
System were purchased from GE healthcare and Fisher Scientific, respectively.
Cell counting kit-8 (CCK-8) was purchased from Dojindo Molecular Technologies
Inc. (Rockville, MD). Ethanol was purchased from the Warner-Graham Company
(Cockeysville, MD). Recombinant human P-selectin/CD62P (Catalog# ADP3050) and human CD62P P-selectin antibody (Catalog# AF137) was obtained
from R&D systems. Lower molecular weight fucoidan powder produced from
brown seaweed extract was obtained from Hi-Q Marine Biotech International Ltd.
(Taiwan). Fluoresceinamine isomer I, 99% was obtained from TCI America. AntiCD44 antibody and PE Mouse IgG2b K isotype control were purchased from BD
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Pharmigen BD Biosciences. Matrigel Basement Membrane Matrix, LDEV-free
(Catalog #356234) was purchased from Corning. 1H-NMR was performed on a
500 MHz Bruker or 600 MHz Varian system using a 5 mm probe at room
temperature. Deuterated water (D2O, 99.9% D); deuterated DMSO and CDCl3
were purchased from Cambridge Isotope Laboratories. FTIR measurements
were performed on a Nicolet IR200 FT-IR instrument using single-reflection ZnSe
ATR crystal. The cell line S2-013, a cloned subline of a human pancreatic tumor
cell line (SUIT-2) was obtained from Dr. Pankaj Singh (UNMC). All cells were
incubated at 37oC in a humidified incubator maintaining 5% CO2 in DMEM
(HyClone, GE Healthcare Life Sciences) with 10% fetal bovine serum and 1%
penicillin/streptomycin. 7-week-old female nude mice were purchased from
Jackson Laboratories (Bar Harbor, ME). 5.0 chromic gut and 5.0 nylon surgical
sutures were purchased from Johnson & Johnson (Somerville, NJ).
Comprehensive diagnostic profile reagent rotor was purchased from Abaxis
(Union City, CA).
2.1 In silico methodology
Molecular docking of sulfated derivates of HA: The X-ray diffraction crystal
structure of mouse CD44 hyaluronan-binding domain (PDB ID: 4MRD) and
human P-selectin protein [PDB ID: 1G1S] were obtained from Protein Data Bank.
Molecular docking was performed to gain deeper insight into the interaction of
modified hyaluronic acid derivatives compared to native hyaluronic acid with
CD44 and P-selectin. The protein structure was cleaned by removing water
molecules and other inorganic ions/atoms in CD44, whereas ions were preserved
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in the P-selectin active site. The HA ligand consisting of 12 units was prepared in
Maestro molecular modelling software (Schrodinger). Docking studies were
performed using Auto-Dock Tools (AutoDock Vina). The grid box of dimensions
40 Å X 40 Å X 40 Å was generated with a 0.5 Å spacing to perform docking.
AutoDock Tools were used to add Gasteiger charges and polar hydrogens to
CD44 and modified hyaluronic acid derivatives. The structures were saved in
*.pdbqt

file

format.

Docking

was

also

performed

using

SwissDock

(http://swissdock.vital-it.ch/) provided as a free web service. The ligands were
docked to the desired protein structures by using suitable docking parameters
allowing the online web service to produce docking results using CHARMM
energies. Similar grid size box dimensions used in AutoDock were used for
SwissDock. The docked ligand file was visualized with the protein using UCSF
Chimera 1.4.
2.2 Synthetic methods
Synthesis and purification of the different sulfate derivatives of hyaluronic
acid
Synthetic procedures for preparation of different sulfated derivatives of
hyaluronic acid and aminopropyl 1-pyrenebutanamide described in literature30,31
and have been modified and optimized and described below.
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Synthesis of TBA salt of hyaluronic acid (HA-TBA): Sodium hyaluronate (10
kDa, 500 mg) was dissolved in 200 mL ultrapure water, which was mixed with 10
g of DOWEX 50WX8-400 ion-exchange resin to allow the substitution of sodium
ions with TBA. This mixture was stirred for twelve hours for the effective exchange
process at R.T. The reaction mixture was then filtered through a 0.45 µm
membrane filter paper obtained from Millipore. This solution was then lyophilized
to produce an off-white powder with a yield of 92% (HA–TBA 10 kDa).
Synthesis of sulfated derivatives of HA-TBA: HA-TBA (off-white powder, 300
mg) was dissolved in a three-neck round bottom flask with 30 mL N,Ndimethylformamide (DMF) under argon with constant stirring for 1 h. Once the
polymer was dissolved, varying amount of sulfur trioxide pyridine complex (3:1
for selective sulfation to yield one sulfate group per unit of HA; 8:1 for moderate
sulfation to yield 2-3 sulfate groups per unit of HA; 12:1 for complete sulfation to
yield 4-5 sulfate groups per unit of HA) were added to the reaction mixture and
allowed to stir for another 15 min at R.T. Once the reactants were dissolved, the
reaction was maintained at 40 °C for selective sulfation for 30 min, 1.5 h for
moderate sulfation, and 3 h for complete sulfation to allow successful reaction
between the sulfate and the hydroxyl groups of HA. The reaction was quenched
with 30 mL nanopure water and pH was maintained at 9-10 at R.T. for 30 min.
Cold acetone was added to the reaction mixture to precipitate the product. The
precipitate was filtered and washed thrice with water and 4 times with acetone.
The product was dissolved in water and dialyzed against 1:1 EtOH:H2O for 4
changes in 24 h followed by 8 changes of ultrapure water in 48 h. This solution
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was then lyophilized yielding an off-white solid with 78% yield for selectively
sulfated HA (ssHA), 62% for moderately sulfated HA (msHA), and 54% for
completely sulfated HA (csHA). Sulfated HA stored at -20OC for future
conjugation.
Synthesis of aminopropyl 1-pyrenebutanamide [PBA]: 1-pyrenebutyric acid
(300 mg) was dissolved in 10 mL methanol with 5% concentrated HCl (11 N) and
refluxed for 8 h at 70 °C. The reaction produced two layers: clear light-yellow color
top layer and dark oil-like bottom layer. The product in the bottom layer was dried
at R.T. and stored at 4 °C, 1-pyrenebutyric acid methyl ester was confirmed in
the bottom layer by 1H NMR and dried under vacuum for 7 days. 1-Pyrenebutyric
acid methyl ester was then dissolved into 10 mL 1,3-diaminopropane and
refluxed at 120 °C for 12 h to produce a clear brown liquid. This solution was then
cooled to 4 °C and PBA was precipitated by cold saturated NaCl solution, washed
with cold water, and dried under vacuum for 7 days producing a 59% yield with
brown powder appearance.
Synthesis of PBA conjugates of different sulfated derivatives of HA:
Sulfated derivatives of HA were dissolved in 20 mL of ultrapure water and stirred
for 15 mins. PBA at 10 wt. % was dissolved into 20 mL DMF at 40 °C under
constant stirring to ensure complete dissolution. NHS and EDC (10× molar ratio
to PBA), were then added to the sulfated HA solution to activate the carboxylic
groups for conjugation. The PBA DMF yellow solution was then added dropwise
to the activated HA solution under constant stirring. The reaction was allowed to
stir at R.T. for 24 h. The reaction contents were then transferred to dialysis tubing
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(MWCO = 3500 Da, Spectrum Laboratories) and allowed to dialyze against 1:1
EtOH:H2O for 24 h, followed by ultrapure water for an additional 48 h with 8
changes. The individual polymer conjugates were removed from the dialysis
tubing and lyophilized for storage at −20OC. Yields of 78% for ssHA-PBA, 72%
for ms-HA-PBA, and 62% for cs-HA-PBA (sNanoCy7.5). This procedures was
adapted from a similar procedure employed to generate HA-PBA-Cy7.5
(NanoCy7.5) nanoparticles32.
Synthesis of cyanine 7.5 amine (Cy7.5 amine) conjugates of different
sulfated HA-PBA derivatives: Three sHA conjugates of PBA were dissolved in
10 mL of ultrapure water and stirred for 30 min. EDC and NHS were dissolved in
above polymer conjugate solution to allow activation on carboxylic groups and
stirred for another 30 min. Next, a solution of Cy7.5-amine 10 wt. % in 10 mL
DMSO was prepared. This solution was added dropwise to the above activated
mixture under constant stirring. The reaction was allowed to proceed with stirring
for 24 h at R.T under dark conditions. The product was purified to remove excess
precursors using dialysis. The reaction mixture was placed in a dialysis bag with
MWCO of 3500 Da and dialyzed against water for 24 h with 4 water changes.
Further, unconjugated Cy7.5 dye was removed via a PD10 desalting columns
with ultrapure water as a mobile phase. The product fractions were collected and
lyophilized to obtain light-green products with a yield of 57-64% for all conjugates.
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Synthesis of fucoidan labeled fluoresceinamine: Fucoidan was conjugated to
fluoresceinamine using the reducing end polysaccharide chemistry which is
employed for conjugation of small molecules. 250 mg of low molecular weight
powder of fucoidan was dissolved in 10 mL of 1,3-diaminopropane (3.5 M) and
stirred for 30 min to allow the reaction mixture to be become clear. 150 mg of
sodium cyanoborohydride (NaBH3CN) was added to the solution slowly stirred
for 24 h at 75OC. After the reaction started, 150 mg of NaBH3CN was added and
stirred for another 72 h at R.T. The reaction was extensively dialyzed
(MWCO:1000 Da) against EtOH:H2O (1:1) for 48 h with 8 changes, followed by
48 h against ultrapure water with 8 changes. The dialyzed product was lyophilized
to obtain a light-yellow product with a yield of 48% and stored at -20 °C. 100 mg
of aminated low molecular weight fucoidan was dissolved in 10 ml of 1M
carbonate buffer (pH 9.5). Fluorescein carboxylate (FITC) was mixed with 10X
molar excess of EDC and NHS in carbonate buffer, stirred for 30 min to allow
activation of carboxylic groups, and added to the polymer solution dropwise to
the reaction was stirred under dark conditions at R.T. for 24 h. The product was
dialyzed [MWCO: 1000 Da] against EtOH:H2O (1:1) for 24 h with 8 changes,
followed by 48 h against ultrapure water with 8 changes. The product was
lyophilized to obtain a dark yellow product with a yield of 64% and stored at -20
°C. Additional purification by PD-10 was carried out to remove unreacted free
Fluoresceinamine, lyophilized powder was dissolved in 1M aqueous NaCl,
precipitated with cold ethanol, and centrifuged at 2000 rpm for 1 h.
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Synthesis of IRDye800 CW amine conjugates with different sulfated HA
derivatives: Different sulfated HA derivatives (10 mg) were dissolved in 10 mL
ultrapure water for 30 min at R.T. Once the polymer dissolved completely, 10x
molar excess of EDC and NHS was added to IRDye800 CW amine aqueous
solution and stirred for 30 min to allow activation of carboxylic groups on sulfated
HA. Next, 10 wt. % eq of IRDye800CW amine was dissolved in 5 mL ultrapure
water and added dropwise to the activated above aqueous solution and stirred
for 24 h protected from light at R.T. The product was dialyzed against water for
24 h with 4 changes, solution was lyophilized and yielded green fluffy powder
(76% yield). Conjugation ratio of IRdye800 to sHA was determined using
standard curve developed for IRdye800 amine in water.
Nanoparticle characterization: Particle size (hydrodynamic diameter HD) and
zeta potential measurements of all sulfated derivatives of HA NPs were
measured by dynamic light scattering (DLS) using ZetaSizer NanoZS90 (Malvern
Instruments; Malvern UK). NPs samples were prepared by dissolving samples in
ultrapure water (1mg/mL) and filtered through 0.45 µm syringe filter. Absorbance
spectra of the NPs were recorded with UV-2600 spectrometer (ThermoFisher
Evolution 220) in water and 1:1 (v/v) mixture of DMSO:H2O. Fluorescence reads
were obtained on a FluoroMax-4, fluorescence spectrometer equipped with a NIR
extended range PMT (Horiba Jobin Yvon; Edison, NJ, USA). Conjugation ratio of
Cy7.5 dye to HA was determined using standard curve developed for Cy7.5 dye
in 1:1 (v/v) DMSO:H2O. Conjugation of the hydrophobic ligand was confirmed by
1

H NMR for all the derivatives of sulfated HA-PBA. Transmission electron
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microscope (TEM) images were obtained for NPs (1 mg/mL concentration),
placed on formavar/silicone monoxide-coated 200 mesh copper grids using
NanoVan negative stain for 30 s and imaged using the FEI Tecnai G2 Spirit TEM
(FEI; Hillsboro, Oregon) at UNMC’s electron microscopy core facility.
2.3. Biophysical evaluation
Fluorescence polarization assay for assessment of binding of different
derivatives of sulfated HA to recombinant human P-selectin protein:
Fluorescence polarization binding assay was performed in a 384-well low-volume
black round-bottom polystyrene NBS microplate (Corning) by measuring the
fluorescence intensities using a Spectromax M5 plate reader (Molecular Devices,
Sunnyvale, CA, USA). Polarization values are reported as millipolarization units
(mP). The fluorescent probe, fucoidan-FITC, synthesized above was serially
diluted in 1X PBS pH 7.4, covering a range of 0.02-50 nM and dispensed in
triplicates in black non-binding 384 well microplate. Blank controls contained only
buffer (10 µL). Total fluorescence intensities were plotted against respective
probe concentrations with GraphPad Prism v7.0 and fitted with linear regression.
Binding of modified sulfated derivatives of HA to recombinant human P-selectin
protein was estimated by generation of a binding curve of probe vs protein in the
concentrations range of 0.02 nM-750 nM to have a wide range for accurate
estimation of KD. Direct binding assay estimation was performed by adding 1 µL
of 0.5 nM fluorescent probe and 10 µl of solution with increasing concentrations
of recombinant P-selectin protein. The final volume of the reaction mixture was
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11 µl in each well, and all measurements were performed in triplicate. The
microplate was shaken for 5 min in dark at R.T before being read by the plate
reader (lex = 489 nm; lem = 538 nm). Background correction of the fluorescence
from the protein alone was obtained for the final mP value. Fluorescence
polarization competition displacement assay was performed using 10 µL of 5 nM
of recombinant protein with 1 µL of 0.05 nM of fluorescent probe and 1 µL of
increasing concentration of unlabeled sulfated HA polymer derivatives (0.02 nM24 µM). The total volume of the reaction mixture was 12 µL in each well.
Fluorescence measurements were made after a 15 min incubation. The data was
fitted and IC50 values were determined using a non-linear least square fit to a
single site binding model (GraphPad Prism v7.0).
2.4. In vitro analysis
2.11. Analysis of P-selectin and CD44 expression on S2-013 cell line:
Expression profiles of CD44 and P-selectin were studied using flow cytometry
analysis (FACS LSRII-green flow cytometer BD). 1 ´ 104 S2-013 cells were
plated in triplicate in 6-well plates and allowed to adhere to the bottom of the dish
overnight. Cells were fixed in 150 µL of 4% paraformaldehyde solution at 37 °C
for 15 mins. The fixing solution was removed by washing the cells with 1X PBS
thrice. Fixed cells were then treated with anti-CD62P antibody (Catalog #ab6632
1:50) and anti-CD44 antibody (Catalog #ab157107 1:200) for 1 h at 37OC. Wells
were then washed thrice with 1X PBS and blocked with 5% BSA for 1 h at R.T.
Cells were then incubated with 75 µL of FITC-conjugated anti-mouse secondary

106
antibody (Millipore AP132F) at 1:100 in blocking solution for 1 h at R.T. in dark
conditions.
Effect of P-selectin and CD44 blocking on uptake of both sulfated HA
nanoparticles and non-sulfated HA nanoparticles: S2-013 cells (1X104 per
well) was seeded in 24-well plate in 1 mL of DMEM media overnight. Cells were
washed with PBS and serum-free media was added to each well. Next, excess
of anti-CD62P P-selectin antibody and anti-CD44 antibody was incubated for 1 h
at 37 °C to allow blocking of P-selectin and CD44 receptors separately in the 24well plate format. NPs solutions were made in serum-free DMEM at equimolar
Cy7.5 dye concentrations of 1.5 mM, added to each well, and incubated for 1 h
at 37 °C. After incubations with NPs, cells were washed thrice with 1X PBS,
trypsinized, and re-suspended in 300 µL of FACS buffer (3% FBS in PBS). A
FACS LSRII-green flow cytometer (BD) was used for all flow cytometry
measurements. A total of 15,000 gated events were acquired per sample, and
the mean fluorescence intensity was plotted in a histogram-based graphical
representation. Each data point is representative of the mean of three
independent measurements on the flow cytometer. Data were analyzed with
FlowJo (Tree Star) software.
Investigation of the effects of PBA and dye (Cy7.5) on P-selectin binding on
S2-013 cells: S2-013 cells (1 ´ 104 per well) were seeded in 24-well plate in 1 ml
of DMEM media overnight. Cells were washed with PBS and serum-free media
was added to each well. Next, excess of anti-CD62P P-selectin antibody was
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added for 1 h at 37 °C to allow blocking of P-selectin receptor separately in the
24-well plate format. Polymer conjugate solutions were made in serum-free
DMEM at equimolar IRdye800 dye concentrations of 1 mM, added to each well,
and incubated for 1 h at 37 °C. After polymer conjugate incubations, cells were
washed thrice with 1X PBS, trypsinized, and re-suspended in 300 µL of FACS
buffer (3% FBS in PBS). A FACS LSRII-green using far-red laser flow cytometer
(BD) was used for all flow cytometry measurements. A total of 15,000 gated
events were acquired per sample and the mean fluorescence intensity was
plotted in a histogram-based graphical representation. Each data point is
representative of the mean of three independent measurements on the flow
cytometer. Data were analyzed with FlowJo (Tree Star) software.
Development of S2-013 tumor spheroid model for studying uptake of dye
vs sHA-IRDye800 conjugates: Matrigel (Matrigel #354234 from Corning,
Corning, NY, USA) was thawed and added to 8-well Nunc™ Lab-Tek™ II
Chamber Slide™ System (50 µL/well) to cover the bottom of each well to serve
as matrix as it is rich in ECM components, such as laminin, collagen, heparin
sulfate proteoglycans, entactin, and several soluble factors. Next, S2-013 cells
(4×103) were mixed with thawed Matrigel along with media and added to Matrigel
coated wells. The growth of the spheroids was monitored using Olympus CKX41
Bright Field, Infinity 1 Luminera microscope over a period of 2 weeks until the
spheroids reached 500 µm in size. Next, free IRDye800 and sHA-IRDye800
polymer conjugates (3 µM concentration of IRDye800) were added to the tumor
spheroids and cultured for 12 h. After washing thrice with 1X PBS and fixing in
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4% paraformaldehyde, the IRDye800 fluorescence in spheroids was measured
with the confocal microscope Zeiss LSM 800 with Airyscan (Jena, Germany) with
20X objective lens with a 1.4 NA using XYZ-stack with 10 µm intervals at 512*512
pixels with imaging acquisitions at 33 Hz. Images were captured and analyzed
with LSM software (Jena, Germany) and processed using Carl Zeiss software.
The spheroids were then treated with trypsin, the obtained single-cell suspension
was washed with PBS and subjected to flow cytometry analysis for determination
of uptake of IRDye800.
Development

of

P-selectin

and

CD44

knockout

cell

lines

using

CRISPR/Cas9 system: CD44 and P-selectin (SELP gene) knockout S2-013
human pancreatic cancer cell lines were generated using CRISPR/Cas9 system.
pLenti-CRISPR v2 vector containing the individual guide RNAs (sgRNAs) was
ordered from GeneScript USA Inc, (New Jersey). The sequences of the guide
RNAs targeting CD44 and and P-selectin (SELP gene) are listed in the
Supplemental Table. Stable CD44 and P-selectin (SELP gene) knockout were
generated by lentivirally transducing human pancreatic cancer cell line S2-013
with pLenti-CRISPR v2 vectors containing gene specific sgRNAs. Lentivirus was
generated by transfecting HEK 293T cells with psPAX2 and pMD2.G and gene
specific pLenti-CRISPR v2 vector in a 3:1:4 ratio. HEK 293T cells were
transfected using Lipofectamine 3000 from Invitrogen. The lentivirus was
collected 24, 48, and 72 h post-transfection. The virus was passed through a 0.45
μm SCFA filter, and 10 µg/mL polybrene was added to the filtered media. The
S2-013 pancreatic cancer cells were transduced with lentivirus targeting CD44
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and P-selectin (SELP gene). Cells were selected for puromycin resistance using
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 1.1 μg/mL
puromycin and 10% FBS for three weeks. Once cells were selected using
puromycin, the cells were cultured in DMEM supplemented with 10% FBS without
puromycin.
Confocal microscopy: S2-013 cells were seeded (105 cells/well) on individual
12 mm Nunc™ glass bottom dishes (Invitrogen, ThermoFisher Scientific, USA)
and left to adhere for 24 h. The cells were treated with sNanoCy7.5 in serum-free
DMEM media and incubated at 37 °C for 1 h. After incubation, cells were washed
thrice with 1X PBS, and then fixed with 4% paraformaldehyde solution for 15 min
at 37 °C. Next cells were treated with 0.25% Triton-X-100 in 1X PBS to
permeabilize the cell membrane, followed by blocking with 1% BSA in 1X PBS.
Next, primary antibody for Rab5 endosomal marker (Rabbit polyclonal IgG, Santa
Cruz Biotechnology Inc., Dallas, TX) was added in 1% BSA 1X PBS solution and
incubated with the cells overnight at 4°C. Cells were incubated with the
secondary antibody (FITC-conjugated anti-rabbit, Millipore AP132F) in 1% BSA
added to each well at room temperature for 1 h at R.T. Cells were then washed
thrice with 1X PBS, and were stained with HCS NuclearMask™ Deep Red Stain
(ThermoFisher Scientific, Catalog# H10294) for 15 mins. Cells were washed and
stored at 4 °C until CSLM imaging. Similar protocol was used for CSLM imaging
of tumor spheroids and P-selectin blocking assay.
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Confocal images were taken with Zeiss 800 Confocal Laser Scanning
Microscope, 60X with 1 µm cell slices. DAPI, Alexa Flour 488 and Alexa Fluor
647 filters were used to detect blue, green and NIR signal from the cells.
Western blot analysis and flow cytometry analysis of CRISPR/Cas9 S2-013
CD44 and P-selectin KO cells: S2-013 cells were washed with 1X PBS and
lysed using radioimmunoprecipitation assay (RIPA) lysis buffer containing
protease inhibitor and EDTA. Cell debris were removed by centrifugation at
13,000 rpm for 20 mins, and the supernatant containing the proteins was
collected. Protein content was quantified using the Bio-Rad Protein Assay dye
(Bio-Rad Laboratories, Inc.) Equal amounts of total proteins (20 μg) were
separated by SDS-PAGE and transferred to nitrocellulose membrane. The
membranes were probed with primary antibodies against actin (1:650, JLA20,
developed by J. J.-C. Lin was obtained from the Developmental Studies
Hybridoma Bank, Iowa City, IA), CD44 (1:5000, ab157107), and P-selectin
(1:100, AF137, R&D Cell Signaling technologies) in TBS with 5% nonfat milk and
0.1% Tween-20 on a rocker overnight at 4OC. Nitrocellulose membrane was
washed with TBST thrice and incubated with anti-mouse IRDye 800CW
secondary antibody (1:15000, LI-COR Biosciences, Lincoln NE) and anti-sheep
IRDye680 secondary antibody (1:10000, Invitrogen, ThermoFisher Scientific) for
1 h in dark at R.T. The membrane was washed with TBST and visualized using
the 700 nm and 800 nm channels of Odyssey® Imaging Systems for assessment
and quantification of protein bands for knockout (KO) cell lines.
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The S2-013 cell lines were plated in 12-well plates and incubated overnight to
adhere to the bottom. Cells were fixed similar to procedures mentioned above
and were analyzed using FACS LSRII-green using far-red laser flow cytometer
(BD) was used for all flow cytometry measurements. Anti-CD44 antibody (1:250,
ab46793) and anti-P-selectin antibody (1:50, BBA34) were used to quantitate the
CD44 and P-selectin expression profiles.
Effect of P-selectin and CD44 KO S2-013 cells on uptake of sulfated HA
nanoparticles and non-sulfated HA nanoparticles: S2-013 cells CD44 and Pselectin KO cells (1X104 per well) were seeded in 24-well plate in 1 mL of DMEM
media overnight. Cells were washed with PBS and serum-free media was added
to each well. NPs solutions were made in serum-free DMEM at equimolar Cy7.5
dye concentrations of 1.5 mM, added to each well, and incubated for 1 h at 37oC.
After NP incubations, cells were washed thrice with 1X PBS, trypsinized, and resuspended in 300 µL of FACS buffer (3% FBS in PBS). A FACS LSRII-green far
red laser flow cytometer (BD) was used for all flow cytometry measurements. A
total of 15,000 gated events were acquired per sample, and the mean
fluorescence intensity was plotted in a histogram-based graphical representation.
Each data point is representative of the mean of three independent
measurements on the flow cytometer. Data were analyzed with FlowJo (Tree
Star) software.
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2.5 In vivo studies
Tumor implantation and NIR imaging: All animal experiments were performed
under approved protocol by the University of Nebraska Medical Center
Institutional Animal Care and Use Committee (IACUC). S2-013 (1X106 cells) were
suspended in 100 µL of 1:1 media:Matrigel (Matrigel #354234 from Corning,
Corning, NY, USA), and injected subcutaneously on the right flank of 5-6-weekold female athymic nude mice (Strain: J:NU, Jackson Laboratory, Bar Harbor,
ME, USA). Tumors were allowed to grow for 4 weeks prior to imaging
experiments. Cy7.5amine (1.2 nmol/mouse), NanoCy7.5 (HA-PBA-Cy7.5 1.2
nmol Cy7.5/mouse), and sNanoCy7.5 (sHA-PBA-Cy7.5 1.2 nmol Cy7.5/mouse)
in 100 µL ultrapure water was intravenously injected via tail vein in mice (n=3
mice per group) once tumors reached 150 mm3. Mice were euthanized 24 h after
the injections. Each mouse was necropsied, followed by relative organ
distribution imaging using the Pearl Trilogy Small Animal Imaging system (LICOR; Lincoln, NE) and Lab FLARE RP1 small animal imaging system (Curadel,
Marlborough, MA) to detect Cy7.5 (800 nm channel) fluorescence from the
contrast agents. Analysis was performed using LI-COR Image Studio 5.0
software to manually draw region of interest (ROI) around tumors and organs to
calculate the signal to noise ratio (SNR); SNR = (average tissue intensity per pixel
in an area of interest)/ (standard deviation of background of interest). Whole-body
imaging of mice and FIGS was performed using the Curadel system as described
previously32,33,34 with exposure of 120 ms for the near infrared laser and 10 ms
for the white light. NIR fluorescence spectra were collected at 1 cm approximate
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distance from the tissue/tumor surface by a handheld spectrophotometer device
that excites at 785 nm and collects emitted light in the NIR window. Laser powers
of 8 (low), 30 (medium low), 80 (medium), 150 (medium high), and 200 (high)
mW were used to collect the NIR emission from the contrast agents in individual
organs.
Histological analysis and fluorescence microscopy: Tumor and organ tissues
obtained from necropsy after FIGS were immediately placed in O.C.T. gel
covering the tissue and frozen at -80OC. Samples were then cut using cryostat
(Leica Biosciences, Buffalo Grove, IL, USA) at a thickness of 5-10 μm at the
UNMC Tissue Sciences Facility. Tumor/tissue sections were stained with
hematoxylin and eosin (H&E)/unstained for NIR confocal scanning fluorescence
microscopy. Representative tumor sections were stained for anti-CD31
proliferation marker (1:150, ab16667 Abcam), anti-hCD44 (1:500, #3570 Cell
Signaling Technology, Danvers, MA, USA), anti-hPselectin (ab6632, Abcam).
Unstained tumor, liver, spleen, and kidney sections were visualized under Zeiss
LSM 800 Airscan (Carl Zeiss, Oberkochen, Germany) using 10X objective with
1.4 N.A. using FITC laser channel for autofluorescence and 687 nm excitation
laser for NIR dye localization. Exposure time of Cy7.5 was constant throughout
all the samples.
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3. Results and Discussions
3.1. Synthesis, characterization, and computational analysis of sulfated
derivatives of HA
Commercially available hyaluronic acid was modified according to scheme
in figure 1A using previously published procedures to produce sulfated HA31.
Understanding crucial hotspots for binding contacts between HA with CD44 and
P-selectin respectively, three sulfated derivatives of HA were prepared using
regio-selective chemistry for synthetic modifications35.
The crystal structure of HA (copolymer of N-acetylglucosamine and
glucuronic acid) complexed with CD44 was solved in 200736, showing key residue
interactions between HA and CD44. Those interactions include hydrophobic
contacts between the N-acetyl group and aromatic ring F83, the side chain of I92
and the disulfide bond between C81 and C101 of CD44; water-mediated
hydrogen bonding between the carboxylate group and F46 and R45 of CD44;
hydrogen bonding between the C6-hydroxy group of HA with F109 of CD44,
which serves in anchoring the structure to the CD44 active site. Based on
previously published computational results, we designed a sulfated derivative of
HA which hindered key residue contacts with F109, thereby decreasing binding
to CD44 protein compared to the native HA37.
The structure of P-selectin protein co-crystallized with post-translated
modified PSGL-1 was solved more than 10 years ago, indicating specifics of
biding partners to P-selectin. P-selectin glycoprotein ligand-1 (PSGL-1) is post-
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translationally modified by glycosylation on sialyl-lewisX tetrasaccharide by
multiple sulfated tyrosine residues (highly negatively charged) near the Nterminus. Interactions between P-selectin and PSGL-1 are mainly dominated by
long-range electrostatic attraction between opposite charges of the binding
partners. The active site of P-selectin lectin binding domain is lined with
numerous positively charged amino acid residues such as histidine, lysine,
arginine, glutamic acid, and strontium ion rendering an overall positive charge of
+9 which is missing in E- and L-selectin, respectively. Importantly, a report
published by Weinhart, et al38 discussed the effect of individual polyanions
synthesized on highly functionalized dendritic polyglycerol scaffold via click
chemistry on P-selectin binding. The authors concluded that the binding potential
increased in the order carboxylate < phosphate < phosphonate ≈ sulfonate <
bisphosphonate < sulfate and tends to increase with the acidity of the anionic
group present on the macromolecular structure38. Building on the importance of
sulfate group in P-selectin targeting, we designed three derivatives of HA by
introducing sulfate group substitutions. The importance of electrostatic
interactions along with partial salt bridges between sulfate groups and active site
of P-selectin was also well correlated experimentally (NMR, SPR) and
computationally to confer selectivity39.
Sulfates (esters) are primarily produced by nucleophilic substitution of
hydroxyl groups. The substitution site and efficiency depend on various
parameters such as sulfating reagent of choice, reaction medium, reaction time,
and temperature40. Sulfation is performed in organic solvents such as
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dimethylformamide (DMF), dimethyl sulfoxide (DMSO), and/or pyridine are most
widely used. Due to the use of organic solvents, HA was synthetically modified
to its tetrabutylammonium salt to allow rapid solubility in organic solvents.
Sulfating reagents, mainly sulfur trioxide-pyridine complex for optimum
substitution rate on polysaccharides, are used in excess compared to available
free hydroxyl groups. Higher temperature of 50-60oC and longer reaction time
have shown to increase the rate of sulfation of the reaction.
In our work, the degree of sulfate substitutions (DS) was controlled by the
addition of different molar ratios of sulfation reagent (sulfur trioxide pyridine
complex in DMF) per repeat unit of HA. Major sulfation sites on HA are the
primary hydroxyl groups being the most reactive, while other (secondary/vicinal)
hydroxyl groups are less susceptible to the attack of the sulfating nucleophile
moiety due to steric hindrance and spatial orientation. The latter can be controlled
by altering the reaction kinetics by changing temperature and reaction time40.
Sulfation of HA occurs at different hydroxyl groups, i.e. at C-2’, C-3’, C-4’,
or C-6’ OH, depending on the concentration of the sulfating reagent, temperature,
and reaction time41. Sulfation is most favored at the C-6 position since it is the
only primary and most reactive hydroxyl in HA31. Selectively sulfated HA (ssHA)
was produced by using 3:1 ratio, moderately sulfated HA (msHA) using 8:1, and
completely sulfated HA (csHA) using 12:1 of moles of sulfating reagent to moles
of HA per repeat unit. The reaction time was optimized for producing ssHA (30
mins), msHA (60 mins), and csHA (180 mins) under constant argon flow.
Sulfation was followed by structural analysis by 1H-NMR: downward shift of the
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C-6 proton peaks on hydroxyl groups (due to the higher electron withdrawing
properties of sulfate groups) was observed from 3.45 ppm to 3.55, 3.62, 3.9 ppm
(yellow arrows in Fig. 1B). Complete sulfation at C-6 was achieved for ssHA,
msHA, and csHA since no peak was observed at 3.45 ppm, and emergence of
new peaks (red arrows) indicated additional hydroxyl sulfation at positions C-2’,
C-3’, and C-4’. All secondary hydroxyls have similar reactivity, msHA and csHA
both containing similar patterns of sulfation between 3.8-4.2 ppm positions. The
increased relative peaks between 4 and 4.4 ppm for csHA indicate a higher
degree of sulfation compared to msHA and ssHA. FTIR data is also conclusive
in Fig. 1D, indicating peak vibrations of C–O–S and S=O (asymmetric and
symmetric) in the range of 800 and 1290 cm-1. This shows the presence of sulfate
moieties for all the derivatives. DS values obtained for ssHA (0.8-1.2), msHA (1.82.2), and csHA (2.9-3) confirmed by elemental analysis data shown in Fig. 1E.
Introducing sulfate groups also increased the negative surface charge of
derivatives of HA (Fig. 1C), thereby shifting the zeta potential to a highly negative
scale for each of the modified variants of HA. Importantly, sulfate groups are
expected to carry a negative charge unaffected in pH ranges (4-8) due to its
sufficiently low pKa, indicating charge integrity of the sulfate group for binding to
the P-selectin protein in physiologic in vivo conditions.
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Fig 1: (A) Synthetic scheme for generation of 3 derivatives of sHA; i: ion
exchange with TBA in H2O, ii: Dowex ion exchange resin; iii: different molar ratios
of sulfur trioxide pyridine complex in DMF. (B) 1H NMR spectra (3.2-4.7 ppm) of
HA and derivatives of sHA with increasing degree of substitution. The peak shift

119
of the methylene protons of C-6 is indicated by yellow arrows, whereas different
vicinal hydroxyl groups by red arrows. (C) FTIR signatures of HA vs different
variants, grey colored portion in the graph indicate S=O (asymmetric and
symmetric) and C-O-S stretching and bending vibrations. (D) Sulfur elemental
analysis for quantification of sulfate content in each of the variants. (E) The zeta
potential (mV) of all derivatives.
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Computational docking analysis of each of the derivatives of HA were
assessed using SwissDock42 and AutoDock43 software packages. Increasing
docking

energies

(indicating

stronger

binding)

with

increasing

sulfate

substitutions on HA to P-selectin protein implying favorable increase in sulfate
groups with increasing binding to active site of P-selectin. We observed
increasing binding trend HA < ssHA < msHA < csHA (Fig. 2). Also, decreasing
binding interactions with CD44 were observed with increasing sulfate
substitutions on HA. Structural modifications on HA were observed to be key
determining factors that influence binding to P-selectin and CD44 proteins.
However, an important consideration should be kept in mind that HA belongs to
family of natural carbohydrates, where controlling the exact molecular weight and
chemical substitution ratio is extremely challenging. Even with precise
stoichiometric substitution ratio under control, it will be virtually impossible to
control such site-by-site modifications. This will lead to the possibility for the less
(or completely unmodified) fragments of the polymer to determine the interaction
with binding partners.
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Fig 2: Computational docking energies for sulfated derivatives of HA against Pselectin and CD44. Images below are images obtained from the docking
program, arrows indicate the binding pose of sulfated HA (orange) and HA (blue)
in the protein structure.
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3.2. Synthesis and characterization of nanoparticles derived from sulfated
HA derivatives
Hydrophobic ligand, 1-pyrenebutanamide (PBA) was synthesized by
formation of methyl ester followed by nucleophilic addition of 1,3 diaminopropane
under reflux to produce PBA (Fig 3A)44 with an amino group as a handle for
conjugation to carboxylic acids of sHA. sHA was functionalized with PBA to form
self-assembling amphiphilic conjugates, the extent of conjugation was
characterized by 1H NMR by observing the aromatic region in the range of 7-8.0
ppm (Figure S3-5).
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Fig. 3: (A) Synthetic scheme for preparation of hydrophobic amino-propyl 1pyrenebutaminde from 1-pyrenebutyric acid. i: Conc. HCl with methanol at 65 C
for 6 h; ii: excess of diaminopropane at 130 C for 6 h (B) Synthetic scheme for
preparation of self-assembled nanoparticles by conjugating Cy7.5 amine NIR
dye. iii: Addition of PBA-DMF solution to EDC NHS activated sHA solution; iv:
EDC NHS activation followed by Cy7.5 addition stirred for 24 h (C) DLS analysis
of size distribution of three different derivatives of sulfated HA nanoparticles.

124

We sequentially modified the nanoparticles with Cyanine7.5 (Cy7.5) using
EDC/NHS conjugation chemistry (Fig. 3B)32, and the extent of chemical
conjugation of Cy7.5 was quantified by UV-vis absorption in water. We observed
the self-assembly induced fluorophore quenching due to the hydrophobic ligand
in the nanoparticles, similar to previous reports on NanoCy7.532. Size distribution
of modified HA nanoparticles was determined by DLS and TEM (Fig. 3C). We
observed a decrease in size of the nanoparticles with increasing sulfate
substitution ratio, which could be a result of electrostatic repulsion provided by
charges around nanoparticles that prevent aggregation/precipitation as shown in
Fig. 3C. Particle size determined by TEM was obviously smaller compared to the
DLS data, as sample preparation demands dehydration to obtain TEM images.
Optical properties were similar to reports published previously32. Disassembly of
NPs in the DMSO solution leads to strong fluorescence as compared to their
quenched state in aqueous media. This is an indication of fluorescence being
quenched due to fluorophores closely packed in a nanoparticle upon its selfassembly.
3.3. Interaction of different sulfated HA derivatives with P-selectin
We designed the FP assay by selecting a suitable ligand which binds to Pselectin with high affinity. Fluorescence polarization (FP) is represented in mP
which is calculated by measuring the intensities of emitted fluorescent light from
a parallel and perpendicular direction w.r.t to excitation plane45. Biomolecules
conjugated or complexed with fluorophores will retain much of the polarizability
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of incident light, and any minute change in polarization can be measured by the
changing ratios of intensities of parallel and perpendicular light, giving a
measurement of ligand binding affinities.
For this, we constructed a low molecular weight fucoidan46 conjugated FITC
ligand by reductive amination with diaminopropane, followed by a reduction with
sodium cyanoborohydride. An accurate measure of binding affinity can be
obtained

when

the

molecular

weight

difference

between

the

ligand

(polymers/carbohydrates) and the large biomolecules is at least 10 times in
magnitude. Carboxyfluorescein was conjugated using EDC/NHS to activate the
carboxylic acid, allowing formation of amide bonds with aminated fucoidan.
Ideally, the attachment of a fluorophore to a ligand should not affect the binding
mode or alter specificity to the receptor. In a reaction mixture, both a fluorescent
ligand and a protein, the observed polarization is always the function of fraction
of the ligand-protein complex.
We performed a probe titration in the assay buffer to determine the
relationship between total fluorescence intensity and probe concentrations. For
0.5 nM of fluorescent probe concentration was selected to have a high
fluorescence intensity at lex = 489 nm to avoid stoichiometric titration above KD
with receptor. Next, serial dilutions of P-selectin recombinant protein (0.02 nM750 nM) were prepared and incubated with the fluorescent ligand, and FP values
were measured. A dose-dependent increase in FP was observed, indicating no
substantial effect of FITC on binding of sulfated derivatives to P-selectin. We
determined the binding affinity of fucoidan-FITC to be 1 nM using nonlinear least
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square fitting to a single-site binding model which is consistent with previous
reports from surface plasma resonance data in literature to be 1.2 nM46.
To determine the interactions of different sulfated derivatives of HA, a FP
displacement/competition assay was set up by optimizing concentrations of 0.5
nM fluorescent ligand and 5 nM of P-selectin, where saturated binding is ensured.
Displacement of fucoidan-FITC from P-selectin was examined by increasing
concentrations of unlabeled derivatives from [0.02 nM - 24 µM], unlabeled
fucoidan was used as a reference standard (Fig. 4B-i). Applying nonlinear least
square fitting to a single-site fitting model, inhibition curves for each of the
derivatives was found. The data shows that the increasing sulfate content leads
to tighter/stronger binding to P-selectin indicating the importance of sulfate
groups for P-selectin binding. Similar observations were reported where multiple
sulfated analogs of HA was tested against IL-8, IL-10, BMP-2, sclerostin, TIMP3, CXCL-12, TGF-b, FGF-1, FGF-2, and AT-III, increasing order of sulfation
bound strongly where non-sulfated HA showed no binding to any of the tested
proteins47. HA is shown to have the least binding which is also in accordance with
literature38. In another report, various semi-synthetic glucan sulfates were shown
to have superior P-selectin inhibitory activity48.
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Figure 4: (A) Synthetic scheme for preparation of fluorescein labelled low
molecular weight fucoidan using reducing end chemistry. (B) [i] KD determination
of the interaction between fluorescein labelled low molecular weight fucoidan and
recombinant human P-selectin protein. [ii] Setup of FP binding assay for the
quantification of reader protein-to- fluorescent probe by measuring linearity of the
total fluorescence intensity of ligand compared to background. [iii] Dose-response
inhibition curve for unlabeled HA and sHA derivatives for determination of KD
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against P-selectin. [iv] Bar graph representation of KD values from competitive
binding assessment in [iii].
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3.4. Binding of sulfated HA nanoparticles from in vitro analysis
P-selectin expression was evaluated in S2-013 which are patient-derived
pancreatic adenocarcinoma cells. They show a positive shift in FACS signal
relative to control analysis implying single population, which was also
confirmed24. CD44 was also evaluated and was positively expressed in S2-013
cells. Furthermore, breast cancer cell line MDA-MB-231, colon cancer cell line
RKO, prostate cancer cell line PC-3 were also observed to overexpress Pselectin by FACS (Fig. 5a). All cell lines tested indicated a positive shift in
fluorescence signal indicating a single population expressing P-selectin. This
suggests the rationale to further pursue the application of sulfated HA as relevant
drug delivery strategy to target P-selectin which is abundantly expressed in
multiple cancer types.
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Fig. 5a: Flow cytometric analysis for P-selectin expression in S2-013 (Pancreatic
cell line), RKO (Colon cancer cell line), PC-3 (Prostate cancer cell line), MCF10A
(Non-malignant breast cell line), and MDA-MB-231 (Breast cancer cell line).
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Evaluation of P-selectin and CD44-dependent internalization in S2-013
cells was carried out by pre-treatment with P-selectin and CD44 specific
antibodies to block all available receptors. Blocking with P-selectin inhibited the
uptake 4-fold, whereas CD44 blockage lead to only marginal decrease in uptake
indicating preference of P-selectin mediated uptake of sNanoCy7.5 over CD44 in
comprehensive FACS analysis (Fig. 5 A-B).
Similarly, traditional HA-based nanoparticles (NanoCy7.5) manifested a
reversal in uptake with minimal effect of P-selectin and several fold decrease in
CD44 mediated uptake (Fig. 5D). To further investigate the effect of hydrophobic
ligand and imaging dye Cy7.5 on binding to P-selectin, a control conjugate of
sulfated HA was designed with IRDye800. Similar results were obtained, implying
that the effect of only sulfate substituent affects P-selectin targeting (Fig. 5E).
Energy dependent internalization process was prevalent at 37 oC compared to 4
o

C (Fig. 5F). We observed a 40-60% decrease in uptake of cells positive for

Cy7.5 fluorescence at 4 oC compared to 37 oC. To investigate the intracellular
trafficking of sulfated derivatives, cells were stained with endosomal marker for
Rab5. As demonstrated previously by flow cytometry, conjugates were readily
detected at the cytoplasm following 1 h incubation (Fig. 5G-H). Co-localization
analysis supported these results. Additionally, confocal laser scanning
microscopy analysis was performed under excess P-selectin antibody conditions
to evaluate the uptake of sNanoCy7.5 at 37oC. Expectedly, blocking decreased
the overall uptake of the nanoparticles, demonstrating mainly P-selectin driven
targeting to cancer cells.
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Figure 5: (A-D) Evaluation of the uptake of NanoCy.5 and NanoCy7.5 in
presence of anti-hCD44 and anti-hP-selectin antibody in S2-013 cells. (E)
Evaluation of uptake of ssHA, msHA, csHA-IRDye800 conjugates in presence of
anti-hP-selectin antibody in S2-013 cells. (F) Temperature dependent effect on
the uptake of three derivatives of HA NPs system at 4OC vs 37OC by FACS. (G-
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H) CSLM images acquired on S2-013 cells with DAPI (blue; nucleus), NIR
(Cy7.5), Green (endosomal marker Rab5 protein) staining to visualize uptake in
presence and absence of anti-hP-antibody. The scale bar represents 50 µm on
all images.
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In order to confirm the uptake of sNanoCy7.5 via P-selectin, P-selectin and
CD44 knockout (KO) cells were generated by CRISP/Cas9 system (Table 1).
msHA based nanoparticles were selected from the three derivatives for the study
due to DS of roughly 2, which ensured retaining their specificities for both Pselectin and CD44. Such characteristics are beneficial for spatiotemporal cancer
cell targeting. CRISPR/Cas9 system was used to knockout the expression of the
individual proteins in S2-013 cells to evaluate binding of sulfated and non-sulfated
HA nanoparticles (sNanoCy7.5 and NanoCy7.5). Guide RNA sequences in
(Table 1) were selected in CRISPR/Cas9 to generate P-selectin and CD44 KO
cells. Western blot and FACS analysis confirmed the elimination of individual
protein expression (Fig. 6 A-B). Knocking out P-selectin further validated its
importance in the uptake of sNanoCy.5 vs NanoCy7.5, indicating that HA plays
no significant role in P-selectin targeting. However, sNanoCy7.5 also showed a
slight decrease in uptake in CD44 KO cells, indicating that the sNanoCy7.5 NPs
do exhibit some degree of CD44 mediated targeting (Fig. 6). This confirms that
sNanoCy7.5 shows both P-selectin and CD44 mediated uptake in S2-013 cells.
Imaging applications were also explored in 3D S2-013 tumoroid model to
observe higher uptake of polymer-IRDye800 conjugate compared to free dye,
indicating improved delivery of imaging agent (Fig. 5b). The results are in
accordance to previous reports on targeted sulfated systems displaying Pselectin mediated uptake. Modulating properties from traditional CD44 targeting
HA to affinity towards P-selectin can now be achieved by precise synthetic
modifications on the polysaccharide backbone.
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Fig 5b: (A) Z-stack model analysis of 3D-tumoroid model of S2-013 for uptake of
IRDye800 by visualization of signal in NIR window using confocal laser scanning
microscopy. (B) (i) H&E staining of 3D-tumoroid of S2-013, (ii) Evaluation of CD44
positive staining in tumoroids, (iii) Evaluation of P-selectin positive staining in
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tumoroids. (C) FACS analysis on lysed tumoroid for quantification of NIR signal
from each of the conjugate syst
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Name

sgRNA sequence

Length

CD44 sgRNA 1

TCGCTACAGCATCTCTCGGA

20

CD44 sgRNA 3

AATATAACCTGCCGCTTTGC

20

SELP sgRNA 2

CAGTTCATGAGCACGTGTTG

20

SELP sgRNA 3

TGTAGTTCCCGATGGTCTCG

20

Table 1: CD44 and SELP guide RNA sequences used for CRISPR/Cas9 KO
studies
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Figure 6: (A-B) (i) Protein expression by western blot analysis on KO cells
derived from CRISPR/Cas9 system. (ii) Signal quantification from NIR fluorescent
western analysis for the KO S2-013 cells. (iii) Confirmation of KO cells by FACS
analysis using anti-hCD44 and anti-hP-selectin antibodies for cell surface protein
expression on S2-013 KO cells. (iv) Quantification of FACS signal. (C) Uptake
analysis of NanoCy7.5 and sNanoCy7.5 on P-selectin and CD44 KO cells by
FACS.
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3.5. Relative biodistribution and image-guided surgery
An in vivo tumor model study was performed to determine if sulfation altered
tumor update and the overall relative biodistribution of the injected NPs. For this
proof of principle study, the S2-013 cell line, which positively expresses both
CD44 and P-selectin, was selected since pancreatic cancer is one of the
deadliest ones with a median overall survival of 15 months and 13.5% survival
rate in 5 years49. Above from in silico to in vitro data, we demonstrated that by
controlling the sulfation patterns on HA, preferential interactions with receptor
specific proteins in the tumor microenvironment can be tuned by understanding
biophysical and biochemical interactions. Binding properties can be fine-tuned by
altering chemical groups, size, and shape of NPs which will impact the
biodistribution and tumor infiltration50. Recently, P-selectin targeting has gained
immense importance in cancer-targeted therapeutics. Shamay et al.19 showed
that P-selectin specific fucoidan-based drug delivery system loaded with
chemotherapeutics (mitogen activated protein kinase kinase inhibitors) had
superior antitumor efficacy. Ferber et al.26 used sulfated dendritic polyglycerol as
nanocarrier for paclitaxel to target P-selectin in glioblastoma cells to treat
glioblastoma

with

increased

therapeutic

efficacy.

Another

multi-stimuli

fucoidan/protamine nanoparticle51 reported by Lu et al. showed improved
inhibitory effect of doxorubicin loaded fucoidan/protamine nanoparticle targeting
P-selectin delivery against highly metastatic breast cancer MDA-MB-231 and
MDA-MB-468 cells. Surprisingly in the report published by Shamay et al.19
revealed high expression of P-selectin in multiple tumors by analyzing RNASeq
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data from The Cancer Genome Atlas (TCGA) database. The TCGA database
reported

amplification

in

melanoma,

liver,

bladder,

ovarian,

lung

adenocarcinoma, and breast cancers. Also, similar analysis from TCGA shown
in report published by Ferber et al.26 showed that high expression of P-selectin
positively correlates with poor patient survival. In almost all the published reports,
normal healthy tissues show relatively absence or lower expression of P-selectin.
This corroborates the importance of P-selectin targeting and the importance of
application of fluorescence image-guided surgery to accurately resect only the
cancerous tissue to avoid relapse.
In this work, the relative biodistribution of near infrared (NIR) nanoformulations of HA, sulfated HA (sHA), and Cy7.5 dye alone was compared in
S2-013 xenograft tumors grown subcutaneously in nude mice using LI-COR
Trilogy imaging system. After 24 h post injections of the contrast agents, organs
were harvested from mice following necropsy to evaluated biodistribution
properties using the LI-COR imaging system represented in Fig 7B. Relative
biodistribution was calculated as signal to noise ratio (SNR) quantified from NIR
fluorescent intensities of each organs corrected for its area32. The overall NIR
fluorescent signal emitted from S2-013 tumors was higher for sNanoCy7.5
compared to NanoCy7.5 and dye alone, and SNR of NanoCy7.5 was higher
compared to Cy7.5, which is in accordance to previously published reports32.
Higher SNR for organs was observed in liver, spleen, and kidney, demonstrating
RES system uptake as an important limitation of HA-based targeted delivery.
Interestingly, sNanoCy7.5 had a 2-fold higher SNR compared to NanoCy7.5 in
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the tumor, suggesting that targeting P-selectin may be a potential added benefit
along with CD44 targeting. Lower liver SNR, higher spleen SNR, and marginally
different kidney SNR of sNanoCy7.5 compared to NanoCy7.5 indicates influence
of different formulation parameters directly impacting the biodistribution profiles
(Figure S9). It should be noted that both nanoformulations included a chemical
conjugated imaging dye instead of a physically entrapped moiety, directly
implying that the targeting ability via P-selectin and CD44 are the major driving
factors for tumor accumulation. Image contrast and change of biodistribution was
compared to surrounding high background tissues such as liver, spleen, kidney,
pancreas, and surrounding muscle in the tumor location. Tumor-to-muscle ratio
was significantly higher for sNanoCy7.5 compared to NanoCy7.5 and Cy7.5.
Higher tumor to muscle ratio was observed for NanoCy7.5 compared to Cy7.5 in
breast and prostate cancer model33, this effect could be due to the heterogeneity
of cancer model and disease type. sNanoCy7.5 also displayed higher tumor-toliver SNR ratios compared to other groups, no significant differences were found
between tumor-to-kidney, tumor-to-spleen, tumor-to-pancreas ratios (Figure S9).
The NanoCy7.5 and sNanoCy7.5 formulations were compared with Cy7.5 dye
alone for applications in image-guided surgery. In previously published literature,
intraoperative imaging was successfully performed using NIR fluorescence
detected by the image-guided surgery system in orthotopic 4T1 and PC3 using
1.2 nmol/mouse for Cy7.532,33. Keeping the dye concentrations constant for both
NanoCy7.5 and sNanoCy7.5 (1.2 nmol/mouse), the tumors were readily detected
with 8 mW “low” excitation power, given the high quantum yield of Cy7.5
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compared to other dyes such as indocyanine green. Whole-animal fluorescence
imaging provided by LI-COR (Figure 7) and Lab FLARE RP1 Curadel
demonstrated that both NanoCy7.5 and sNanoCy7.5 could detect tumors in the
NIR window (laser excitation on 785 nm), whereas surrounding skeletal muscle
showed no NIR signal (Figure 7). Whole body imaging after 24 h demonstrated
brighter signal from tumor injected with sNanoCy7.5 compared to NanoCy7.5.
Semi-quantitative analysis of spectroscopic signatures of NIR fluorescence from
spectroscopic pen showed that sNanoCy7.5 resulted in 2-fold stronger signal,
however not significant, based on AUC of the intensity vs wavelength curve,
compared to NanoCy7.5 (Figure 7a). Taken together, the results could
potentially imply that a higher payload of imaging agent was being delivered due
to plausible spatiotemporal targeting of both CD44 and P-selectin. However, it is
to be taken into consideration that importance of both P-selectin and CD44
expression on tumor cells for targeting would depend on accessibility,
permeability, and morphology of the tumor microenvironment. Nevertheless,
precise understanding of the targeted system in the tumor warrants further
investigations.
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Figure 7: Biodistribution of contrast agents (Cy7.5, NanoCy7.5, and
sNanoCy7.5). (A) Representative whole animal NIR imaging using LI-COR and
Curadel system after 24 h post intravenous injection of the contrast agent.
Spectroscopic signals from excised tumor and muscle (ie quadriceps femoris
muscle) of a representative mouse from each of the groups shown at the bottom.
(yellow arrow indicates the tumor) (B) Representative NIR fluorescence images
from excised ex vivo harvested 24 h after intravenous administration of indicated
contrast agent (1.2 nmol of Cy7.5/mouse for Cy7.5-amine, NanoCy7.5, and
sNanoCy7.5). All images were collected at 800 nm channel overlaid onto the
brightfield photograph from the Pearl Trilogy imaging system. Organ labels: 1:
tumor(s), 2: heart, 3: Lung, 4: pancreas, 5: spleen; 6: muscle (i.e. quadriceps
femoris muscle), 7: Bone, 8: Kidney. 9: liver, 10: Stomach, 11: Small intestine,
12: Large intestine, (C) Quantitative summary of fluorescence intensity of organs
where bars represent the average pixel signal-to-noise ratio (SNR; mean ± s.d)
of N = 3 mice, *p < 0.05, **p < 0.01, unpaired multiple t-test. (D) Tumor-to-muscle
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ratios comparison across the groups, *p < 0.05, **p < 0.01, unpaired multiple ttest.
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Fig 7a: Tumor-to-organ ratios in S2-013 tumor bearing nude mice. (A) Tumor-tomuscle, (B) tumor-to-spleen, (C) tumor-to-kidney, and (D) tumor-to-liver SNR
ratios obtained from the ex vivo imaging in Fig. 2. *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001 one-way ANOVA with Tukey’s multiple comparisons test. (E-F)
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Summary of spectroscopic signals of excised tumor and muscle based on AUC of
the intensity vs. wavelength curves. Values are expressed as mean ± SD (n = 3 for
all other groups). *p < 0.05, **p < 0.01; as determined by two-way ANOVA with
Tukey’s method for multiple comparisons. #p < 0.05; as determined by unpaired ttest.
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The distribution and targeting capability of sulfated and non-sulfated system
was studied by histological analysis of frozen tumor sections was performed by
confocal imaging for distribution and localization of NIR dye. Sections were
counter-stained for P-selectin, CD44, and CD31 expression to corroborate the
targeting capabilities of sulfated and non-sulfated HA nanoparticles. Twenty-four
later, substantial amount of contrast agent was still located in tumors, as exhibited
by a strong fluorescence signal. To understand where sNanoCy7.5 and
NanoCy7.5 locates within the tumor, we stained S2-013 tumor sections for Pselectin, CD44, and CD31. P-selectin and CD44 were highly expressed in S2013 tumors as depicted in Fig. 8, Fig. 8a. Higher NIR fluorescence was observed
from tumors injected with sNanoCy7.5, which correlates with highly colocalization
of P-selectin and CD44 expression. At the same time, NanoCy7.5 uptake in the
tumor only correlates with high CD44 expression and not P-selectin expression.
CD31 staining showed that S2-013 tumors are moderately vascularized (Fig. 8,
Fig. 8a). This indicates that sNanoCy7.5 tumor uptake in cancer cells was highly
dependent on both CD44 and P-selectin expression profile whereas NanoCy7.5
was only dependent of CD44 expression. Thus, uptake of sNanoCy7.5 was
greatly enhanced compared to NanoCy7.5, illustrating the importance of
modulating targeting properties of HA. This suggests that the dual-targeted
sulfated HA system works on both P-selectin and CD44 expressing cancer cells.
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Figure 8: NIR distribution in tumors analyzed by confocal laser scanning
microscopy after harvesting, fixing, and sectioning. Representative tumor
sections were stained with DAPI (nuclear stain), anti-hP-selectin antibody (a cell
surface protein, P-selectin), and anti-CD31 (endothelial marker).
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Figure 8a: NIR distribution in tumors analyzed by confocal laser scanning
microscopy after harvesting, fixing, and sectioning. Representative tumor sections
were stained with DAPI (nuclear stain), anti-hCD44 antibody (a cell surface protein,
CD44).
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Conclusions
We demonstrated the potential of HA sulfation to influence its binding
affinity to P-selectin, which also applies to nanoparticles derived from sulfated
HA. Assessment of CD44 and P-selectin targeting modulation by sulfated HA was
studied by in silico docking computational algorithms, binding measurements by
FP, in vitro binding assessments by flow cytometry, and validation by
CRISPR/Cas9 KO system, and in vivo evaluation by fluorescence image-guided
surgery. This approach can be applied to study a wide range of tumor types
expressing

both

microenvironment

CD44
of

most

and

P-selectin,

cancers.

considering

Targeting

the

expression

of

dynamic
specific

biomarkers/pharmacophores can be utilized by implementing a “dual-edge
technique”

over

single-targeted

for

better

therapeutic

outcomes

for

chemotherapeutics and delivery of imaging agents. In summary, the data herein
suggests that sulfated HA is a promising candidate for improved imaging through
dual-targeting of P-selectin and CD44 biomarkers. Future studies for this work
entails detection of metastatic lesions, using different cancer orthotopic models,
deciphering changes in pharmacokinetic profiles52, and survival analysis after
tumor removal using image-guide surgery mandates the study of this classes of
synthetic derivatives of HA.
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CHAPTER IV:

ENGINEERING NOVEL FLUORESCENT NANOPARTICLES FROM
NATURALLY DERIVED HYALURONIC ACID AND AMINO ACIDS
FOR BIOMEDICAL APPLICATIONS
ABSTRACT
Nonconjugated fluorescent polymers have been increasingly investigated
to improve the biocompatibility and theranostic application of conventional
fluorescent materials. However, the accessibility of such systems remains
challenging due to the scarcity of non-toxic nonconjugated nanomaterials and
lack of explanation for the fluorescence mechanisms. Herein, we develop a novel
fluorescent material by introducing sub-fluorophore imine groups (-C=N) by
chemical conjugation/physical immobilization of naturally available hydrophobic
amino acids to the hyaluronic acid (HA) polymer chain. This in-situ self-assembly
was carried out under one-pot “green chemistry” conditions and resulted in
enhancement of the fluorescence intensity of novel fluorescent organic
nanoparticle (FONP) species. The FONPs exhibited high water solubility due to
the existence of hydrophilic functional groups on its surface, acceptable stability
profiles, superior biocompatibility, and high emission quantum yield. The FONPs
emitted strong excitation-dependent fluorescence. In addition, our FONPs
demonstrated drug carrier properties with enhanced drug loading and delivery of
the anticancer drug doxorubicin (DOX) in contrast to the free DOX in cancer cells
and 3D tumor spheroids. Results demonstrate the efficacy of a novel fluorescent
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HA-based multifunctional system, with potential future applications in imageguided drug delivery.
Keywords: Non-conjugated fluorescent polymer dots, hyaluronic acid, amino
acids, biocompatible, drug delivery vehicle.
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Introduction
In recent decades, there has been immense interest in the development of
functional fluorescent polymeric nanomaterials for bioimaging, drug delivery,
bioanalysis, and chemical sensors due to their biocompatibility, green synthetic
approaches,

and

easy

functionalization1,2.

Previously,

development

of

fluorescent organic nanomaterials involved sophisticated time-consuming
synthetic steps, complicated purification techniques, and use of harsh nonenvironmentally friendly organic solvents. Other drawbacks of conventional
fluorescent nanomaterials include, limited scale-up interventions and poor water
solubility. These drawbacks in development bolstered research into exploring
alternative strategies to generate fluorescent nanomaterials without the need for
chemically conjugating a fluorescent dye. Therefore, the genesis of a nonconjugated polymer dots (NCPD) was initiated by many researchers in past years
by polymerization, cross-linking, hydrothermal, and physical approaches. These
methods resulted in the generation of highly water soluble materials with bright
fluorescence and improved biocompatibility3.
NCPDs do not typically possess a conjugated fluorescent dye4 but instead
contain numerous multiple sub-fluorophore chemical groups (-C=N, -N=O).
These groups upon suitable immobilization in the polymeric network, show
increased fluorescent properties. The heteroatom-containing double bonds are
traditionally not regarded as fluorophores, which make it uniquely appealing. A
non-fluorescent precursor material can be used to form a novel fluorescent

159
material by precisely tuning the chemical reaction for applications in chemical and
biological fields. The mechanism for the generation of fluorescence in a nonconjugated system is referred to as crosslinked-enhanced emission (CEE)3,
which is different from aggregation-induced emission (AIE)5,6. CEE functions
when a small amine-rich organic molecule upon hydrothermal reaction conditions
crosslinks into a large polymeric matrix leading to enhanced fluorescence due to
decreased vibrations and rotations of sub-fluorophores7.
Recently, several groups have reported the use of the hydrothermal method
with natural materials, such as chitosan8, PEI-glucose9, PEI-sucrose10, PEIformaldehyde11, PEI-carbon tetrachloride12, PEI-PLA, PEI-starch13, honey14,
ginger15,

phenol-hexamethylenetetramine16,17,

ethylenediamine-carbon

tetrachloride, polydopamine18, and cocoon silk19, to prepare water-soluble
fluorescent NCPDs. During the hydrothermal treatment, the amine-rich precursor
and large saccharide molecule react to form fluorescent aggregated structures
for use as biomaterials.
In this work, we contributed to the field of non-conjugated fluorescent
polymeric nanoparticles by using naturally derived hyaluronic acid (HA) and
various amino acids to synthesize self-assembling FONPs via a Schiff-based
conjugation reaction (Scheme 1). Water-soluble blue FONPs were fabricated
under mild conditions without the need for any harmful organic solvents.
Furthermore, by utilizing spectroscopy, the fluorescence origin of HA-derived
FONPs have been proposed and explored. In this study, we not only have created
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a new class of biocompatible fluorescent nanomaterials with excellent fluorescent
properties and good water dispersibility but also have demonstrated application
in bioimaging and drug delivery platforms.

Scheme 1: Schematic representation for generation of hyaluronic acid based
FONPs.
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Material and Methods
Sodium hyaluronate, 10 kDa, was purchased from Lifecore Biomedical (Chaska,
MN). All water was purified with Barnsteadt Ultrapuret Diamond system (Thermo
Scientific; Waltham, MN). 96-well tissue culture plates (Falcon), 12-well tissue
culture plates, Desalting PD10 columns and dialysis tubing (MWCO = 3500),
Nunc™ Glass Bottom Dishes (12 mm), and Nunc Lab-Tek II Chamber Slide
System were purchased from Fisher Scientific (Pittsburgh, PA). Doxorubicin was
purchased from Ark Pharma (Catalog #AK-72874) and Indocyanine green (ICG),
5-(N-Ethyl-N-isopropyl)amiloride

(Catalog

#1154-25-2),

Chlorpromazine

hydrochloride (Catalog # 69-09-0), Methyl-β-cyclodextrin (Catalog #332615),
Quinine sulfate (Catalog #1597005) and bovine serum albumin (BSA) from
Sigma-Aldrich (St. Louis, MO). L-Tryptophan (Catalog # A10230), L-Tryptophan
benzyl ester (Catalog #H63385), and L-Proline benzyl ester (Catalog #L15618)
were purchased from Alfa Aesar. Ethanol was purchased from the WarnerGraham Company (Cockeysville, MD). Anti-CD44 antibody and PE Mouse IgG2b
K Isotype Control were purchased from BD Pharmigen BD Biosciences. NMR
spectra were recorded on a 500 MHz Bruker or 600 MHz Varian system using a
5 mm probe at room temperature. Deuterated water (D2O, 99.9% D) was
purchased from Cambridge Isotope Laboratories. FTIR measurements were
performed on a Nicolet IR200 FT-IR instrument using single-reflection ZnSe ATR
crystal. Penicillin/streptomycin (100X solution) was purchased from Corning. Cell
lines (MDA-MB-231, and MCF10A cells) were obtained from American Type
Culture Collection (Manassas, VA) and were grown in RPMI-1640 (HyClone, GE
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Doxorubicin resistant cell lines were obtained from Dr. Rakesh Singh at UNMC.
All cells were incubated at 37oC in a humidified incubator with 5% CO2. Matrigel
Basement Membrane Matrix, *LDEV-free (Catalog #356234) was purchased
from Corning.
Preparation and purification of the hyaluronic acid derived amino acid
fluorescent nanoparticles
Hyaluronic acid amino acid fluorescent nanoparticles were synthesized by
dissolving HA (25 mg) in 25 mL ultrapure water and stirred continuously for 30
mins at R.T. The next step included adding 12.5 mg of tryptophan, tryptophan
benzyl ester, and proline benzyl ester in three separate reactions flasks, and
stirring for another 30 mins at R.T. Once the reaction mixture was clear, the
reaction mixture was placed in an oil bath maintained at 60-80 °C with constant
stirring for 5 h. Subsequently, the reaction mixture was allowed to cool overnight.
The cooled solution was purified against ultrapure water by dialysis. Reaction
contents was placed in porous cellulose bag (molecular weight cut-off: 3500 Da)
and dialyzed with a total of 8 changes over 48 h to remove all unreacted
reactants. The dialyzed product was collected, lyophilized to yield a white fluffy
product for all three precursor amino acids (78% yield for HA-tryptophan, 81%
HA-tryptophan benzyl ester, and 73% HA-proline benzyl ester nanoparticles),
and stored for further analysis at -20 °C.
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Synthesis, purification, and loading efficiency of doxorubicin loaded
hyaluronic acid derived amino acid fluorescent nanoparticles
20 mg of all three hyaluronic acid amino acid nanoparticles were dissolved
in ultrapure water and stirred for 30 mins to allow complete dissolution.
Doxorubicin was dissolved in ultrapure water (100 µg/mL), added dropwise to the
aqueous solution containing the hyaluronic acid NPs to 20 wt. %, and stirred for
24 h protected from light. The reaction mixture was placed in a porous cellulose
bag (molecular weight cut-off: 3500 Da) and dialyzed with a total of 8 changes
over 48 h to remove all unreacted doxorubicin. After completion, the residual
unconjugated doxorubicin was removed by passing the dialyzed product through
a PD-10 desalting column with ultrapure water as a mobile phase. The
doxorubicin loaded fraction was collected and was lyophilized to obtain light red
fluffy product. (HA-tryptophan Dox = 42% yield, HA-tryptophan benzyl ester =
51%, HA-proline benzyl ester = 49%). The drug loading content were measured
by UV-vis (ThermoFisher Evolution 220) by generating a calibration curve of
doxorubicin concentrations (0.001-0.5 mg/mL). The loading efficiency was
calculated as follows:

𝐷𝑟𝑢𝑔 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 𝑤𝑡% =

𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑜𝑥𝑜𝑟𝑢𝑏𝑖𝑐𝑖𝑛 𝑙𝑜𝑎𝑑𝑒𝑑
∗ 100
𝑡𝑜𝑡𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑜𝑥𝑜𝑟𝑢𝑏𝑖𝑐𝑖𝑛 𝑙𝑜𝑎𝑑𝑒𝑑 𝑁𝑃
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Synthesis, purification, and loading efficiency of Indocyanine green (ICG)
loaded hyaluronic acid derived amino acid fluorescent nanoparticles
20 mg of the tryptophan hyaluronic acid amino acid conjugate was
dissolved in ultrapure water and stirred for 30 mins to allow complete dissolution.
Indocyanine green (ICG) was dissolved in ultrapure water (0.1 mg/mL), added
dropwise to the aqueous solution containing the hyaluronic acid NPs to 20 wt. %,
and stirred for 24 h protected from light. The reaction mixture was placed in a
porous cellulose bag (molecular weight cut-off: 3500 Da) and dialyzed with a total
of 8 changes over 48 h to remove all unreacted ICG. After completion, the
residual unconjugated ICG was removed by passing the dialyzed product through
a PD-10 desalting column with ultrapure water as a mobile phase. The ICG
loaded fraction was collected and was lyophilized to obtain light green fluffy
product. (HA-Tryptophan ICG = 61% yield). The dye content was quantified by
UV-vis spectroscopy (ThermoFisher Evolution 220) by generating a calibration
curve of ICG concentrations (1-10 μM).
Physico-chemical characterization of hyaluronic acid derived amino acid
fluorescent nanoparticles
The morphology of the fluorescent nanoparticles was visualized by
transmission electron microscopy (FEI Tecnai G2 Spirit microscope; 2% aqueous
methylamine vanadate, pH 8, was used for negative staining operated at 100 kV
onto a carbon-coated copper grid at R.T.). The chemical structures of all amino
acid nanoparticles were studied with 1H and

13

C NMR spectroscopy (Bruker
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Avance-III HD, 500, and 600 MHz respectively). FT-IR spectra were recorded on
the Nicolet IR200 FT-IR instrument using single-reflection ZnSe ATR crystal. Xray photoelectron spectra (XPS) were obtained on a Kartos Axis Ultra Imaging
spectrometer, Spectra of C(1s) (275−295 eV binding energy), O(1s) (525−545
eV binding energy), and N(1s) (380−420 eV binding energy) as well as survey
scans (0−1100 eV) were recorded with a tilt angle of 45°. The atomic
compositions were corrected for atomic sensitivities and measured from highresolution scans. XPS and FT-IR data were acquired for dry samples. Absorption
and fluorescence spectra were recorded on a ThermoFisher Evolution 220 UV–
vis spectrophotometer and Horiba Jobin Yvon FluoroMax 4 spectrofluorometer,
respectively, in 10 mm quartz cells with a slit width of 5 nm. Colloidal properties
were studied using a Malvern Zetasizer Nano ZS90 dynamic light scattering
instrument. The quantum yield of the fluorescent nanoparticles was obtained by
comparing fluorescence emission of reference dye (quinine sulfate in 0.5 M
H2SO4, Φ= 0.5420).
Stability assessment of hyaluronic acid derived amino acid fluorescent
nanoparticles
The fluorescence intensities of the amino acid nanoparticles were
evaluated in different buffers ranging in pH from 1-14 by measuring the maximum
emission intensity. Photo bleaching experiments were performed using a 365 nm
UV lamp, 4 Mw cm-2, and measuring the peak emission intensity over time period
of 0-10 h to evaluate stability. Influence of ionic strength on the stability of the
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fluorescent nanoparticles was evaluated by dissolving in salt (NaCl)
concentrations ranging from 0-2 M, and fluorescence intensities were recorded
at maximum emission intensity.
Cell viability assay
The cell viability of unloaded and loaded drug/dye HA-amino acid
nanoparticles was evaluated using the CCK-8 assay (Dojindo). Cells [MDA-MB231, MCF10A, CI66, and Ci66-Doxorubicin resistant] (5000 cells/well) were
seeded in a 96-well plate with media (RPMI 1640, 10% FBS, 1% P/S), and
allowed to adhere to the bottom of the well overnight. After 24 h, cells were
incubated with different concentrations of unloaded HA-amino acid nanoparticles
for 24 and 48 h, drug loaded nanoparticles for 24, 48, and 72 h, and dye loaded
nanoparticles for 24 h. After incubation with various treatments, the cells were
exposed to CCK-8 reagent (1:10 dilution) and incubated for 1-4 h at 37 °C. Plates
were analyzed with a microplate reader (Synergy HTX Multi-mode reader BioTek)
at 450 nm. The values obtained were directly proportional to the number of
metabolically active cells present. Six replicate wells were used for each
concentration, and the experiment was repeated three times. Relative cell
survival was expressed as absorbance relative to the untreated cells.
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Apoptosis assay
CI66 and CI66-Doxorubicin resistant cells (3 x 105 cells/well) were seeded
in 12-well plates and allowed to adhere overnight. After 24 h, cells were treated
for 12 h at 37 °C with unloaded and drug-loaded nanoparticles. Cells were then
washed with PBS thrice, trypsinized and centrifuged at 3500 rpm for 5 mins. The
cell pellet was suspended in 100 µl Annexin-V-FITC binding buffer in FACS
tubes, followed by addition of Annexin-FITC (5 µl) and propidium iodide (5 µl).
Samples were incubated for 30 mins at R.T. under dark conditions, as per
manufacturer’s recommendations in the Annexin V Apoptosis Detection Kit I
(556547. BD Biosciences). Stained cells were analyzed using a BD LSRII flow
cytometer at the Flow cytometry core facility, UNMC.
Confocal microscopy:
CI66 and CI66-Doxorubicin resistant cells were seeded (105 cells/well) on
individual 12 mm Nunc™ Glass Bottom Dishes (Invitrogen, ThermoFisher
Scientific, USA) and left to adhere for 24 h. The cells were treated with unloaded
and drug loaded FONPs in serum-free DMEM media and incubated at 37 °C for
1 h. After incubation, cells were washed thrice with 1X PBS, and then fixed with
4% paraformaldehyde solution for 15 min at 37 °C. Next, cells were treated with
0.25% Triton-X-100 in PBS to permeabilize the cell membrane, followed by
blocking with 1% BSA in 1X PBS. Next, primary antibody for Rab5 endosomal
marker (Rabbit polyclonal IgG, Santa Cruz Biotechnology Inc., Dallas, TX) was
added in 1% BSA 1X PBS solution and incubated with the cells overnight at 4 °C.
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Cells were incubated with the secondary antibody (FITC-conjugated anti-rabbit
Millipore AP132F) in 1% BSA at room temperature for 1 h. Cells were then
washed thrice with 1X PBS, and were stained with HCS NuclearMask™ Deep
Red Stain (ThermoFisher Scientific, Catalog# H10294) for 15 mins. Cells were
washed and stored at 4°C until CSLM imaging.
Confocal images were taken with Zeiss 800 Confocal Laser Scanning
Microscope, 60X with 1 µm cell slices. DAPI, Alexa Flour 488 and Alexa Fluor
647 filters were used to detect blue, green and NIR signal from the cells.
Development of CI66 and CI66-Dox resistant tumor spheroid model for
studying uptake of FONPs
Matrigel (Matrigel #354234 from Corning, Corning, NY, USA) was thawed
and added to 8-well Nunc™ Lab-Tek™ II Chamber Slide™ System (50 µL/well)
to cover the bottom of each well to serve as matrix as it is rich in ECM
components, such as laminin, collagen, heparin sulfate proteoglycans, entactin,
and several soluble factors. Next, CI66 and CI66-Dox res cells (4 × 103) were
mixed with thawed Matrigel along with media and added to Matrigel coated wells.
The growth of the spheroids was monitored using Olympus CKX41 Bright Field,
Infinity 1 Luminera microscope over a period of 2 weeks until the spheroids
reached 500 µm in size. Next, unloaded and drug loaded FONPs were added to
the tumor spheroids and cultured for 12 h. After washing thrice with 1X PBS and
fixing in 4% paraformaldehyde, the blue and doxorubicin fluorescence in
spheroids was measured with the confocal microscope Zeiss LSM 800 with
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Airyscan (Jena, Germany) with 20X objective lens with a 1.4 N.A. using XYZstack with 10 µm intervals at 512*512 pixels with imaging acquisitions at 33 Hz.
Images were captured and analyzed with LSM software (Jena, Germany). The
spheroids were then treated with trypsin to obtain a single-cell suspension,
washed with PBS, and subjected to flow cytometry analysis for determination of
uptake of FONPs.
Evaluation of FONP endocytosis mechanism:
The effects of several membrane endocytosis mechanisms were
investigated on HA based nanoparticles. CI66 cells were incubated in a 12-well
plate at a density of (105 cells/well) and left for 24 h to adhere and cover the
bottom of each well. After 24 h, cellular uptake inhibitors such as 150 mM ethyl
isopropyl amiloride [EIPA] (inhibitor of micropinocytosis), 1.8 mM methyl-bcyclodextrin (inhibitor of caveolae-independent endocytosis), 10 µg/mL
chlorpromazine (inhibitor of clathrin-mediated endocytosis), and 5 mg/mL of HA
(inhibitor of CD44-mediated uptake) were pre-incubated for 1 h to block
respective endocytosis pathways. Next, similar concentration of FONPs to those
used in confocal microscopy/cytotoxicity assessments were used to evaluate the
uptake by flow cytometry. Fluorescence (ex/em 488 nm/520 nm) was detected
using a FACS LSRII-green laser (BD). A total of 10000 gated events were
acquired per sample, and the mean fluorescence intensity was plotted in a
histogram-based graphical representation. Each data point is representative of
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the mean of three independent measurements on the flow cytometer. Data were
analyzed with FlowJo (Tree Star) software.

171
Results and Discussions
Preparation, characterization, and fluorescence origin of hyaluronic acid
based fluorescent nanoparticles
We report for the first-time the generation of a novel fluorescent hyaluronic
acid-amino acid nanoconjugates by hydrothermal Schiff base formation. This is
referred to as a reaction between a species containing an active aldehydic group
and a nucleophilic rich-amino group yielding a product containing C=N or imine
bond as primary fluorescent centers interlocked in a polymeric mesh network21.
Hyaluronic acid (HA), a non-sulfated, non-toxic glycosaminoglycan biopolymer,
consists of alternating (1–3)-β linked N-acetyl-D-glucosamine and (1–4)-β linked
D-glucuronic acid. It presents abundant conjugatable groups making it uniquely
suited for the design of novel polymeric systems22. It has been reported that HA
degrades with increasing temperatures from 60-120 °C23, leading to rupture of
bonds between vicinal diols forming carbonyl functional groups. These groups
can be made available for conjugation with amino-rich compounds forming Schiff
base- like molecules. Amino acids are the essential building blocks in proteins.
Their unique zwitterionic properties from both amino (-NH2) and carboxyl group
(-COOH) with varying side chains24 lead dictate different functional properties of
proteins.
Due to their unique properties, amino acids can be exploited as functional
groups for the formation of various nanoparticles. Hydrophobic amino acids such
as tryptophan, phenylalanine, proline can be conjugated to a hydrophilic
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component to modulate amphiphilic self-assembling properties, and thus to
control dynamics of the nanoparticle formation.
In this context, the biocompatible amino acids can be used as ideal building
blocks for the preparation of nanoparticles. In this approach, non-fluorescent HA
when reacted with non-fluorescent amino acids under controlled hydrothermal
conditions, results in the formation of blue fluorescent HA nanoparticles. A Schiff
bond is produced in the reaction due to the Amadori rearrangement reaction25,26.
The rearrangement reaction can also be credited to increased collision between
reactants to facilitate formation of FONPs. All reactants and products formed are
highly water-soluble, overcoming most of the challenges encountered during
multi-step synthetic processes, making it an example for scale-up production of
FONPs.
The final product that was obtained from each of the starting amino acids
emitted a strong blue fluorescence under a UV lamp 365 nm excitation source.
The exhibited blue fluorescence can be attributed to the generation of a new
absorption band in the UV region between 280-320 nm that can be attributed to
n

π* transition for C=N bonds27. Several Fourier transform infrared (FTIR)

absorption band signatures for C-N stretching and bending vibrations between
1120-1135 cm-1, broad -OH band between 3320-3340 cm-1, C=N stretching
vibrations at 1620-1640 cm-1, and C-O stretching between 1020-1060 cm-1 were
observed for HA-based FONPs (Fig. 1B). In addition, the 1H-NMR spectral
analysis highlighted overlapping regions between 7-8.00 ppm belonging to
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hydrophobic groups of amino acids and N=CH protons (Fig. 1C). We also
performed

13

C NMR to detect peaks between 170-180 ppm, confirming the

formation of C=N group in the fluorescent HA nanoparticles28 (Fig. 1a-c).
X-ray photoelectron spectroscopy (XPS) was used to investigate the
surface state and composition of FONPs, indicating the presence of C, N, and O
elements in Fig 1E. Analyzing high-resolution C1s spectra, peaks at 283.7 eV,
282.9 eV, and 285.9 eV were assigned to C-C, -C-O, and -C=N bond signatures
respectively. These results demonstrate the successful formation of Schiff bond
C=N resulting from condensation between HA and amino acids.
Formation of amphiphilic water-soluble spherical nanostructures was due
to the conjugation of HA hydrophilic backbone and hydrophobic amino acids with
pockets of hydrophobic C=N sub-fluorophore units. The nanoparticles were found
to have a negative (ζ) zeta potential of -17 to -19 mV (Fig. 1D), owing to the
negatively charged carboxylic groups (-COOH) of HA29. The FONP possess the
hydrodynamic diameters between 200-400 nm by as measured by dynamic light
scattering (DLS) and TEM30 (Fig. 1F). Overall, the preparation of HA FONPs was
simple and environmentally friendly in the absence of organic solvents, making
this system particularly attractive in the field of nanomaterials as compared to
other methods of preparation.
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Figure 1: (A) Synthesis of fluorescent organic nanoparticles from precursor HA
and amino acids. (B) FTIR spectral signatures of HA derived FONPs, grey
colored portion in the graph indicate C=N, C-N, =C-H, C-O, N-H stretching and
bending vibrations (C)

1

H-NMR spectra (7-8 ppm) indicating successful

conjugation of hydrophobic ligand and C=N formation, (D) Zeta potential (mv)
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analysis, (E) High resolution C1s spectra of all nanoparticles from XPS showing
the C-C, C=N, and C-O bond energies, (F) Size distribution analysis of all
nanoparticles with TEM insets.

176

Figure 1a: 13C NMR spectra of HA-tryptophan FONP.
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Figure 1b: 13C NMR spectra of HA-tryptophan benzyl ester FONP.
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Figure 1c: 13C NMR spectra of HA-proline benzyl ester FONP.
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Both starting materials lack UV-sensitive chromophores or p-aromatic
conjugated building blocks as the main source of fluorescence emission31. The
exact photophysical mechanism is still under rigorous investigation; however, in
published literature, it is shown that small molecular rotors such as C=N upon
efficient immobilization or hindering bond rotations/vibrations significantly
restricts radiative transition decay32. Restriction of bond rotations lead to an
increase in electronic density on sub-fluorophore groups leading to fluorescence,
in a process previously coined as covalent-bond enhanced emission (CEE). This
leads to the formation of new excited states, thus making the resulting HA FONP
fluorescent. We expect that p-p interactions between the hydrophobic groups will
significantly hinder rotation of sub-fluorophore -C=N leading to further
enhancement of fluorescence. Excitation wavelength, when varied from 280-420
nm (Fig 2), resulted in a broad emission peak with no dramatic change in the
maximum wavelengths. We hypothesized this was due to the presence of
numerous sub-fluorophores and diverse photoluminescent states in the corepolymeric

structure.

HA

derived

FONP

also

exhibited

lex-dependent

photoluminescent property (Fig. 2)indicating the presence of multiple excited
sites similar to other reports on FONPs33.
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Figure 2: Photoluminescence and UV-vis absorption spectra’s of FONPs in
comparison with precursor amino acids and determination of fluorescence origin
from NaBH4 reduction method.
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To verify the importance of employing a large macromolecular reactant
(HA) for effective immobilization of small molecule in the polymeric network, we
utilized citric acid and tryptophan to form small-molecule imine complex, and no
significant fluorescence was detected. However, if carbonization reactions (150200 °C) were employed, the formation of carbon dot was observed with size
ranges between 2-6 nm. This highlights the importance of using a polymeric
starting material along with small molecule precursors to effectively generate
FONPs.
To further investigate the role of -C=N bond on the origin of fluorescence,
Schiff bond can be reduced to its -NH-CH2- form34. This reduced form possesses
increased molecular rotations over single bonds, abolishing fluorescence
properties due to an increase in radiative energy loss. FONP derived from Schiffbased chemistry on reduction with 0.1M NaBH4 also losses its characteristic
fluorescence property, demonstrating the importance of Schiff bonds as primary
fluorescence-emitting moieties. Loss of UV absorbance between 280-320 nm
and fluorescence emission between 380-550 nm was also observed (Fig 2). In a
previous report, fluorescent PEI-formaldehyde polymer particles upon reduction
with NaBH4 displayed increased fluorescence instead of loss of fluorescence.
This phenomenon was attributed to the formation of p-p* transition of -C=C bond
in a double Schiff bond formation. This confirms that HA-based FONP possesses
only single Schiff bond elements similar to other reports of PEI-glucose10 and
PEI-starch13 derived FONPs.
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Moreover, stability assessments were performed in buffers in pH ranging
from 2-10; 0-2 M NaCl; and photostability studies were performed under
irradiation for 10 h under 365 nm excitation. No drastic change in fluorescence
intensity or photobleaching was observed in solutions with pH ranges 4-9,
different NaCl concentrations, and upon irradiation of UV light for 10 h (Fig. 2a).
However, at extremely low and high pH, complete disappearance of fluorescence
was observed. This can be attributed to the destabilization of the chemical
structure

of

HA

or

increased

concentrations

of

H+

and

OH-

interrupting/preventing electronic transitions to excited states35. Furthermore, no
apparent precipitation was observed at R.T. during long-tern storage for 10
weeks (Fig. 2b) These results demonstrate that the HA derived FONPs possess
a good stability profile and can be expected to remain stable for at least 12
months when stored either at R.T. or at 4°C.
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Figure 2a: Stability assessment in different salt conditions, photostability, and
buffer conditions for 3 HA-derived FONPs.
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Figure 2b: Picture of HA-tryptophan FONP formulation at 0 and 10-week time
interval for visual stability analysis.
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Additionally, we investigated the effects of preparation time and
concentrations of reactants on fluorescence. Increased concentrations of both
reactants lead to increase of blue fluorescence intensity. Increase in temperature
(above 100 °C) for more extended periods lead to the formation of carbon
dots/formation of black sticky semi-solid mass instead of polymer dots. Therefore,
a 1:0.5 ratio of HA to amino acids was chosen at 80 °C for 5 h for optimal
fluorescence property and preparation of fluorescent nanoparticles.
Biocompatibility, cellular uptake mechanism, and cellular imaging
application of FONP
The bioimaging field is aimed at imaging and visualizing advanced
biological processes. Lower toxicity of fluorescent imaging probes is required for
the use of HA-derived FONPs for applications in cellular labeling. We investigated
the cytotoxicity profiles of the prepared HA-FONPs by conducting a CCK-8 assay
in two breast cancer cell lines (MDA-MB-231 and CI66) and non-malignant breast
cell line (MCF10A). An average of 97% of all cells remained alive across all
concentrations at two-time points (24 and 48 h) for all the FONP derivatives
indicating very low toxicity profiles (Fig 3B). Since the FONPs displayed
acceptable cytotoxicity profiles with no significant differences in toxicity levels
across all concentrations, design of all preliminary bioimaging studies in CI66 cell
line were carried out at 4 h incubation period. FONPs were successfully
internalized by cells and primarily localized in the cytoplasmic space, which was
monitored through a confocal scanning laser microscope. Merged images in

186
Fig.3A show strong blue fluorescence in the cytoplasmic space from FONPs,
green from the endosomal marker, and cyan from nuclear stain. The FONPs were
observed to not have entered the nucleus of the cells.
We further investigated the endocytosis mechanism responsible for uptake
of HA-derived FONPs by flow cytometry analysis. Major cellular uptake pathway
inhibitors36 used were methyl-β-cyclodextrin (inhibitor of caveolae-independent
endocytosis),

ethyl

isopropyl

amiloride

(inhibitor

of

micropinocytosis),

chlorpromazine (inhibitor of clathrin-mediated endocytosis), and HA (inhibitor for
CD44-mediated uptake). CD44 and clathrin-coated pits mainly governed
endocytosis of FONPs (Fig. 3a). Higher expression profiles of CD44 across all
cell lines are expected to be the major driver for the internalization of HA-derived
FONPs. Although there are multiple published reports on the use of FONPs for
bioimaging applications, to the best of our knowledge, there are no reports on
using HA-amino acid-based FONP materials. Above results display potential of
FONPs as an imaging tool in a 2D cell culture system; however, this cannot
predict the behavior of NPs system in 3D models.
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Figure 3a: Evaluation of endocytosis mechanisms for HA-FONPs using different
endocytosis inhibitors.
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To address this, we prepared a multicellular tumor spheroid model from
CI66 cells and used it as a complementary system to evaluate the in vitro
bioimaging performance of FONP penetration using confocal microscopy and
flow cytometry. Further analysis of fluorescence intensity from FONPs confirmed
penetration in the spheroids to about 4-7 layers of cells (Fig. 3C). Next,
quantitative measurements on uptake of FONPs in the spheroids were measured
by single-cell FACS analysis by trypsin digestion to produce a single-cell
suspension. Consistent with above confocal observations, all the FONPs
possessed high uptake in tumor spheroids (Fig. 3C). Drug delivery applications
to cancer tumors using HA derived FONPs can be utilized for delivering a higher
dose of the encapsulated chemotherapeutic drug for the increased likelihood for
effective cancer cell killing. The achieved penetration depth of the FONPs is
promising but can be improved by surface functionalization with varying targeting
peptides, antibodies, and polysaccharides, which would significantly improve
delivery to solids tumors and enhance anti-cancer effect.
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Figure 3: (A) CSLM images of CI66 cells incubated with HA-derived FONPs for
4h. Blue- FONPs, Green- Endosomal marker, Cyan-pink- Nuclear stain. (B) CCK8 assay performed on CI66 cells incubated with library of HA-derived FONPs in
MDA-MB-231, CI66, and MCF10A cell lines. (C) Penetration of FONPs in CI66derived tumor spheroids; blue- FONPs, yellow- nuclear stain, accumulation of
FONPs in CI66 cells from spheroids indicated as mean fluorescence intensity
after flow cytometry analysis. Results are shown as mean ± SD.
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Combined drug/imaging agent delivery properties in 3D tumor model:
We next evaluated the possibility of utilizing FONPs as a drug delivery
vehicle for potential therapeutic applications in image-guided drug delivery37.
Firstly, doxorubicin (DOX) was selected as the model drug due to its intrinsic red
fluorescence and overlapping spectral region between the emission of FONP and
absorption of DOX. Interestingly, DOX was chosen due to its high absorptivity in
the spectral region of the absorption spectra of FONPs providing favorable
spectral overlap, ideal for efficient energy transfer via the Forster energy transfer
mechanism (FRET)38. Secondly, DOX, also known as Adriamycin is widely used
in treatment regimens for the treatments of various solid cancer tumors39. The
DOX loading content was quantified by measuring the fluorescence intensity of
DOX.
According to the DOX UV-Vis absorption calibration curve (excited at 485
nm), the drug loading content in each of the FONP was calculated as 9.3 wt.%
for HA-tryptophan, 9.8 wt.% for HA-tryptophan benzyl ester, and 6.7 wt.% for HAproline benzyl ester FONPs. It is to be noted that polymeric nanomedicines have
a typical drug loading capacity of around 10 wt.%40,41. We observed a relatively
higher drug loading for the tryptophan derivatives compared to proline derivative,
due to synergistic p-p interactions of benzyl groups along with electrostatic
interaction (charged and hydrogen bonding) of indole ring of tryptophan, which is
missing in proline benzyl precursor. DOX loaded FONP nanoparticles exhibited
a spherical morphology with a size distribution of hydrodynamic diameter
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relatively larger size of approximately 20-30 nm indicating successful loading of
DOX. These were also confirmed by TEM images (Fig. 4C).
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Figure 4: (A) Schematic representation of DOX loading onto HA-derived FONPs.
(B) Fluorescence spectra of three DOX-loaded FONPs representing quenching
of parent blue signal and appearance of DOX fluorescence (520-620 nm). (C)
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Size distribution analysis by DLS and TEM inset images for each of the
nanoparticles.
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Furthermore, we also observed complete quenching of the blue
fluorescence (400-500 nm) from FONPs and appearance of DOX fluorescence
(520-640 nm) from the nanoparticles (Fig. 4B), indicating efficient FRET between
the FONP and DOX loaded in the polymeric mesh. Similar results were obtained
when indocyanine green (ICG), an FDA approved dye, which is used for imageguided surgery, was loaded onto HA-tryptophan FONP. Similar FRET-like
behavior with emission in the near-infrared window was observed. Fluorescence
spectra showed emergence of peak in the 700-800 nm region when FONPs were
excited between 300-380 nm, indicating energy transfer between the
nanoparticle and loaded ICG (Fig. 4a). UV-vis spectra showed both absorbances
from FONP and ICG implying entrapment of ICG (Fig. 4a). From the UV-Vis
calibration curve, ICG loading content was found to be 8.6 wt. %. ICG loaded
particles also demonstrated an increase in size in similar ranges to DOX loaded
FONPs. Confocal laser scanning microscopy imaging of CI66 cells incubated with
ICG-loaded FONP revealed cyan-blue signal from FONPs in the cytoplasmic
region when excited at 320 nm (Fig. 4a).
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Figure 4a: (A) UV-vis absorbance spectra for ICG loaded HA-tryptophan FONP.
(B) Fluorescence spectra with different excitation wavelengths (300-800 nm) (C)
Size distribution by DLS. (D) Overlap region of NanoICG (ICG encapsulated in
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HA-PBA) and HA-Tryptophan ICG FONP. (F) Confocal laser scanning
microscopy in CI66 cells, Cyan-ICG, Blue-FONP.
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Energy transfer from a non-conjugated polymeric system to dye/drug
loaded is believed to mainly occur via energy diffusion within polymer host
followed by energy transfer to guest molecule depending on the packing
symmetry. The donor’s FONP fluorescence was not completely quenched when
loaded with ICG which could be attributed to the formation of twisted
intramolecular charge transfer states, lower energy diffusion or transfer
efficiency, and inappropriate lattice packing42. Although the packing of DOX and
ICG might not be similar, it is difficult to accurately predict the randomness of the
distribution of dye/drug within the polymeric matrix. To elucidate a piece of
detailed information about energy transfer rate, decay kinetics, and excited-state
lifetimes, sophisticated instrumentation such time-resolved fluorescence
measurements will be required to be considered for future studies.
Future directions could include utilization of the remarkable “lightharvesting” properties of FONP43 to obtain bright, red-shifted emission spectrums
beneficial for near-infra red image-guided surgery in animals for accurate
detection of positive margins44.
Moreover, to explore cancer cell killing efficiency of DOX loaded FONP, we
determined the cellular viability of CI66 and CI66-DOX resistant cells with
different formulations using the CCK-8 assay. We observed in CI66 cells that HAtryptophan DOX loaded FONP had a half-maximal inhibitory concentration (IC50)
of 1.82 µM and HA-tryptophan benzyl ester with an IC50 of 1.42 µM exhibiting
higher cell killing (Fig. 5B) compared to free DOX of an IC50 of 2.2 µM. The lower
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IC50 values for the tryptophan derivatives confirmed enhanced cytotoxicity as an
effect of the nanoformulation of DOX within FONP, compared to free DOX
treatment under identical conditions in CI66 cells.
Confocal microscopy showed DOX was predominantly localized in the
nuclear compartment at its designated site of action, with limited fluorescence
from the cytoplasm after 4 h incubation period (Fig. 5C). We anticipate that DOX
will be released from the nanosystems under low pH conditions (4.5-5.5) in the
endosomal-lysosomal compartment of the cancer cell to release DOX and target
the nucleus, where its primary therapeutic impact is expected to occur by
intercalating between base pairs of the nucleotides due to its planar rigid
structure. We also confirmed the cell viability and confocal microscopy results
above by an apoptosis analysis using flow cytometry. It is well known that DOX
can cause dissipation of the mitochondrial membrane, activation of p53 protein,
generation of reactive oxygen species, and DNA fragmentation45 triggering
apoptosis and potential necrosis, initiating sequential cell death46. Treatment with
DOX loaded FONPs lead to a higher % of apoptotic/necrotic cells in the Q2
compartment (AnnexinV and PI positive) compared to free DOX alone (Fig. 5E),
which was consistent with IC50 analysis from cytotoxicity assays.
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Figure 5: (A) CSLM images of CI66 cells incubated with HA-derived DOX loaded
FONPs for 4h. Blue- FONPs, Green- Endosomal marker, Cyan-pink- Nuclear
stain, Red- DOX. (B) IC50 cell killing assessments on CI66 cells at three different
time points. (C) Surface plot images of CI66 tumor spheroids treated with DOX,
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HA-tryptophan-Dox, HA-tryptophan benzyl-DOX, and HA-proline benzyl DOX (D)
Penetration of FONPs in CI66-derived tumor spheroids, accumulation of DOXloaded FONPs in CI66 cells from spheroids indicated as mean fluorescence
intensity after flow cytometry analysis. Results are shown as mean ± SD. (E) CI66
cells were treated as indicated and stained with AnnexinV-FITC and Propidium
Iodide (PI) using FITC Annexin V Apoptosis Detection Kit I and quantified with
flow cytometry. The percentage of late apoptotic/necrotic (Annexin V+/PI+) are
denoted in each of the panel.
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To investigate where cells resistant to doxorubicin would affect the
intracellular drug accumulation, uptake of the three DOX loaded FONPs were
tested in CI66-DOX resistant cells. Much higher DOX fluorescence intensities
from flow cytometry were observed for the tryptophan and proline conjugates with
an equivalent dose of DOX for the same period of time under similar conditions
(Fig. 5a). These results indicate that DOX loaded FONP could be retained for a
longer time and not be detoxified as quickly as free DOX by multi-drug resistant
efflux proteins47. The cellular uptake of DOX (free DOX or its equivalent in FONP)
was also investigated by confocal laser scanning microscopy (Fig. 5a).
Compared with the cells treated with free Dox, the red fluorescence intensity was
higher in cells treated with the tryptophan derivatives. Furthermore, the red
fluorescence intensity in the nuclei of the cells treated with Dox-FONPs was
higher compared to the nuclei of cells treated with free Dox. Diffused lower signal
was observed in the cytoplasm indicating that the FONP might have some affinity
towards cellular organelles to facilitate sustained drug release. These results
indicate that doxorubicin resistant cells internalize the Dox-FONPs, slowly
release the drug for accumulation in the nuclei. This might be due to the balance
of uptake and efflux of the nanocarrier and the diffusion of a small-molecule
chemotherapeutic drug.
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Figure 5a: (A) CSLM images of CI66-Doxorubicin resistant cells incubated with
HA-derived DOX loaded FONPs for 4h. Blue- FONPs, Green- Endosomal
marker, Cyan-pink- Nuclear stain, Red- DOX. (B) IC50 cell killing assessments on
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CI66-Dox resistant cells at three different time points. (C) Penetration of FONPs
in CI66-Dox resistant-derived tumor spheroids, accumulation of DOX-loaded
FONPs in CI66 cells from spheroids indicated as mean fluorescence intensity
after flow cytometry analysis. Results are shown as mean ± SD. (E) CI66 cells
were treated as indicated and stained with AnnexinV-FITC and Propidium Iodide
(PI) using FITC Annexin V Apoptosis Detection Kit I and quantified with flow
cytometry. The percentage of late apoptotic/necrotic (Annexin V+/PI+) are
denoted in each of the panel.
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The differences in IC50 values and DOX content in both CI66 and CI66-Dox
resistant cell lines, strongly suggest that drug loaded FONP complexes may elicit
a higher antitumor efficiency and extended therapeutic effect. This can be
attributed to the higher payload delivery of the drug which is conducive to slower
prolonged drug release intracellularly within the cancer cell, providing a valuable
platform for targeted cancer chemotherapy.
Therefore, in both non-resistant and resistant cancer cells, incubation with
DOX loaded FONPs resulted in not only a higher degree of cell death but also a
higher degree of apoptosis, in comparison to free DOX. Similar reports were also
observed for DOX-loaded carbon dots48 derived from carbonization of milk with
increased delivery to ACC-2 adenoid cystic carcinoma cell line.
Drug delivery applications were also tested in a 3D tumoroid model using
both CI66 (Fig. 5C) and CI66-DOX resistant cell (Fig. 5a) lines to investigate the
penetration of particles. We observed strong DOX fluorescence from tumoroid
treated with HA-tryptophan and HA-tryptophan benzyl ester derivatives
compared to HA-Proline benzyl ester (Fig. 5D and Fig. 5a). Flow cytometry data
corroborated that HA-Tryptophan and HA-Tryptophan benzyl ester both had a
significant higher cellular DOX fluorescence intensity than DOX treated ones
(Fig. 5D), which is most likely owing to DOX being delivered at a higher amount.
The lower DOX delivery can be attributed to the low DOX loading in proline
derivative compared to tryptophan derivatives. Similar penetration depths were
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observed with confocal results obtained from unloaded FONPs of about 4-7
layers of cells.
These results, along with above data, provide initial evidence that HAderived FONPs could be potentially used for drug delivery applications with
extensive in vivo investigations to help translate from a pre-clinical setting to a
clinical environment. Future applications could potentially include photodynamic
therapy, hypoxia-activated therapy, and combination drug treatment therapy for
the success of the in vivo tumor assessment studies.

Conclusions
We developed a new system of a novel fluorescent non-conjugated FONPs
from non-fluorescent biocompatible hyaluronic acid and amino acids via Schiff
base green chemistry. Merits of this system include high water dispersibility, ease
of synthesis via green chemistry approaches, blue fluorescent properties,
excitation dependent emission fluorescence, extraordinary stability profile,
exceptional biocompatibility, and possible drug delivery carrier applications to
cancer cells. Fundamental properties of fluorescence arising from the formation
of Schiff bond and self-assembling properties from tuning hydrophobicity on the
choice of amino acids has been discussed. Furthermore, we anticipate that this
system can also be utilized for biosensing purposes for different metal ions based
on the combined effect of electron transfer and inner-filter effect49.
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More importantly, future directions of this work can be extended to study
and control physiochemical properties by the use of other hydrophobic amino
acids such as phenylalanine or tyrosine and improve process development to
control FONPs size which dictates in vivo biodistribution and pharmacokinetic
profiles. Photoluminescent properties can also be tuned to the NIR region by use
of dopants (Nitrogen, sulfur, phosphorus) for applications image-guided surgery.
Targeting ligands can also be conjugated to direct FONPs to specific biomarkers
on cancer cells for increased therapeutic outcomes. This work is significant in the
field of non-conjugated polymer research because it provides understanding of
the generation of the nanomaterials, implications in bioimaging, and improvement
of available drug delivery platforms of cancer chemotherapeutics.
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CHAPTER V:
FUTURE DIRECTIONS
Summary of CD44 binding studies
In this work, we have shown that hyaluronic acid when modified to
deacetylated HA (deHA), sulfated HA (sHA), and deacetylated sulfated HA (sdeHA) forms, have lower binding affinity to CD44 compared to natural HA. The
decrease in binding is due to hindrance in recognition of key molecular
fingerprints in the HA polymer backbone to essential amino acids in the active
site of CD44. Future studies will evaluate different molecular weights of HA and
intracellular downstream pathways.
Other chemical modifications that can be explored are selective
methylation/arylation of HA. Methylation of HA has shown increased long-term
stability and higher in vivo stability. Methylation could also lead to the recognition
alteration with CD44 and could also potentially be re-targeted to other receptors,
which require relatively hydrophobic groups in a polymer for binding. Longer in
vivo stability could be attributed to resistance to hyaluronidases for degradation
similar to sulfated HA. Newer imaging/drug delivery nanoparticle systems could
be developed from methylated HA for assessment of in vivo performance in
image-guided surgery.
Another approach would be engineer CD44 mutants to mutate the vital
amino acids for recognition of HA and modified HA derivatives using more robust
biophysical techniques such as surface plasma resonance (SPR) and bio-layer
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interferometry (BLI). This will ensure that the interactions are indeed as described
from computational results. However, the major drawback of chemical
modifications on HA has been the non-location-specific conjugation and
polydispersity, making it difficult to control the chemical reaction on a molecular
level precisely. Nonetheless, HA is a highly useful biocompatible polymer, and its
future applications will doubtlessly expand in biomedical research.

Summary of P-selectin binding studies
In this work, HA was synthetically modified to retarget selectin protein (Pselectin) for delivery of imaging dye Cyanine 7.5 for image-guided surgery. HA
was regio-selectively sulfated to yield three polymers with different sulfate
substitution ratios. Completely sulfated HA (csHA)> moderately sulfated HA >
selectively sulfated HA in decreasing bound to P-selectin. Moderately sulfated
HA was used to target both P-selectin with high affinity and CD44 with lower
affinity as a multi-targeted system. Higher tumor accumulation was detected for
sulfated HA nanoparticles was observed compared to non-sulfated HA
nanoparticles in S2-013 tumors. Higher RES uptake was also observed for the
sulfated HA nanoparticles as size ranged from 200-500 nm, which limit the overall
dose reaching the tumor. Future directions will evaluate approaches to the
optimized size of NPs and avoid macrophage recognition system to increase
tumor delivery.
Size of the nanoparticle can be reduced to smaller size ranges by use of
the lower molecular weight of HA (2-5 kDa) or addition of ultrasonication steps
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during nanoparticle process optimization. Use of click chemistry instead of
EDC/NHS conjugation chemistry might affect the overall NP product, however,
iterative optimizations will be needed to design the system of interest.
One approach that can be utilized to evade the macrophage machinery is
by developing a protein-carbohydrate delivery system. CD47, a protein which is
known as a marker for “self” is present in all almost all cell types. Macrophages
contain a receptor called SIRP-1-a which recognizes CD47 and signals the “Do
not eat me” signal. This process prevents the detection and engulfing of the
body’s own cells and help identify foreign objects such as nanoparticles. The
design of the protein-carbohydrate system will include (i) Synthesis of HA or sHA
polymer conjugates of NIR dye of interest; (ii) Conjugation of CD47 to HA or sHAdye conjugate by lysine-mediated conjugation using EDC/NHS machinery,
followed by purification. There are two potential positive outcomes of this design;
first, targeting would mainly be driven by recognition by macrophages and also
by macrophage-mediated penetration to tumors; or P-selectin/CD44 mediated
recognition of the polymer conjugated to the protein. Drawbacks of this system
could be to ascertain the exact mechanism of tumor uptake and the role of each
component in the delivery system. Nonetheless, this approach might attract new
channels for the design of novel-HA based delivery systems.
A better understanding of the in vivo performance of the sulfated system vs
non-sulfated system would be to evaluate the image-guided surgery efficacy in
an orthotopic pancreatic cancer model of S2-013. Subcutaneous tumor models
in which tumor is grown in the back hip, providing optical protection of the NIR
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signal from the tumor from visceral organs such as liver and kidneys. Future
studies will also require survival surgery and direct comparison of contrast agents
between target tissues. A larger animal model would be appropriate to investigate
the contrast agents between tumors and other underlying tissues in a surgical
setting. Large animal models that could be used are canines and porcine.
However, price and availability are major limitations for routine analysis. One
appropriate animal may be rats, which are substantially larger than mice while
smaller than many other research species.
Non-invasive preclinical imaging methods are critical for the development
of newer classes of contrast agents. Pharmacokinetics is the study of what the
body does to a drug influencing biodistribution and clearance properties. Future
studies will be to evaluate different pharmacokinetic parameters (half-life in the
distribution phase (t (1/2)α), terminal half-life (t (1/2)β), volume of distribution (Vc), the
volume in steady-state(Vss), the blood clearance (clearance), the estimated
concentration at time 0 (C0), Hepatic clearance, and Area under the curve (AUC)
of various contrast agents (non-sulfated HA nanoparticles and sulfated HA
nanoparticles) in Sprague-Dawley rats.
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Summary of fluorescent organic nanoparticle studies
In this work, HA was synthetically modified with natural amino acids to yield
fluorescent conjugates (FONPs) via cross-linked enhanced emission effect
(CEE). Tryptophan, Tryptophan benzyl ester, and proline benzyl esters were
utilized as hydrophobic ligands to help drive the self-assembly process of HA
nanoparticles. The FONPs have been investigated as less toxic and more
biocompatible substitutes for quantum dots. FONPs have sizes exceeding 200
nm with no smaller size ranges and lower polydispersity analogs. Carbon dots in
size ranges of 10-30 nm obtain higher tumor accumulation.
Future directions to stimulate preparation of smaller sizes of FONPs would
involve use of lower molecular weights of HA, ultrasonication methods, and use
of cross-linking agents. This approach could also lead to improved colloidal
stability and reduced degradation rates.
The fluorescence generation was associated with formation of multiple subfluorophoric C=N (Schiff bonds) groups in the polymeric matrix. Future studies
will involve elucidating the exact underlying fluorescence mechanism by using
advanced spectroscopic techniques such as time-resolved spectroscopy. A
deeper understanding of the role of C=N bond in fluorescence generation can be
studied using different structural analogs. Methods to control the bond rotations
around C=N could include addition of bulkier groups and studying addition of
different chemical substituent around C=N bond and studying the energy bad gap
differences by HOMO and LUMO. Other methods to study the influence of could
be the addition of dopants on fluorescence could be use of nitrogen, phosphorous
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or halogens. Such chemical entities have been reported to influence the excited
state dynamics in a fluorescent species.
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